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ABSTRACT 
Since its discovery nearly a century ago, a-tocopherol (vitamin E) research has 
been mainly focused on its ability to terminate the cycle of lipid peroxidation in 
membranes. Nitrobenzoxadiazole fluorescent analogues were made previously to study 
the intracellular transfer of vitamin E in cells. However, these molecules were reportedly 
susceptible to photobleaching while under illumination for transfer assays and 
microscopy. 
Here is reported the synthesis of a series of fluorescent analogues of vitamin E 
incorporating the more robust dipyrrometheneboron difluoride fluorophore (BDP-a-Tocs; 
Aex = 507 nm, Aem = 511 nm). C8-BDP-a-Toc 42c, having an eight-carbon chain between 
the chromanol and fluorophore, wa<; shown to bind specifically to a-tocopherol transfer 
protein with a dissociation constant of approximately 100 nM. Another fluorescent 
analogue of vitamin E with a thienyl derivative of BODIPY that is excited and fluoresces 
at longer wavelengths (Aex = 561 nm, Aem = 570 nm) is in development. 
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1 INTRODUCTION 
1.1 Vitamin E 
1.1.1 Discovery and Structure 
Herbert Evans and Katherine Bishop discovered vitamin E in 1922 while studying 
the ability for female mice to carry to term a normal pregnancy when raised on controlled 
diets of casein, cornstarch, and lard.1 They concluded that mice lacking this vitamin are 
able to conceive, but the fetus eventually dies and is resorbed by the mother.1 The formal 
name that wa<.; given to this compound was tocopherol, which is derived from tocos 
(Greek: offspring) and phero (Greek: to bring forth). It is also called 'vitamin E' because 
of its discovery shortly after vitamin D.2 
During its structural elucidation in 1938, it was revealed that there are a total of 
eight molecules belonging to the vitamin E family (Figure 1). Vitamin E contains a 
chromanol head and an isoprenoid tail that is thirteen carbons in length.3,4 Different 
degrees and positions of methylation on the chromanol, a<.; well as unsaturation along the 
tail, result in these different molecules (vitamers), making 'vitamin E' rather more a 
general term that describes a family of structurally similar molecules. Vitamin E is split 
into two main categories: (1) the tocopherols that contain fully saturated isoprenoid tails 
and (2) the tocotrienols that contain geranylgeranyl phosphate-derived tails with 
unsaturation at positions 3', 7' and 11,.5 Both categories contain a stereocentre at position 
2, but the tocopherols contain two more at positions 4' and 8'. The form that is most 
readily incorporated and retained in animals is (RRR)-a-tocophero1.6 
1 
chromanol isoprenoid tail 
I I 
R, 
HO 
R2 4' 8' R2 
.&' .&' 
CH3 tocopherol CH3 tocotrienol 
R/ R2 Tocopherol Tocotrienol 
CH3 CH3 a-tocopherol a-tocotrienol 
CH3 H p-tocopherol p-tocotrienol 
H CH3 y-tocopherol y-tocotrienol 
H H b-tocopherol b-tocotrienol 
Figure 1. Structures and names of the eight vitamers of vitamin E 
1.1.2 Dietary Intake 
Humans cannot synthesize vitamin E; instead it must be acquired by diet. The 
suggested daily intake of vitamin E (a-tocopherol equivalents) is 15-30 milligrams.6 
Vitamin E is synthesized exclusively by plants and can be found in leafy vegetables, 
cereals and oils.3 The distribution of vitamers in these sources is not equal, however. a-
Tocopherol predominates in safflower and sunflower oils whereas y-tocopherol is mostly 
prominent in com, soybean and canola oils.6,7 It has been found that the intake of y-
tocopherol is two to four times greater than a-tocopherol in the North American diet 
because foods are often cooked or fried with oils containing large amounts of y-
tocopherol. This is not true for those living in Europe because these foods are cooked 
with oil that are richer in a-tocopherol.7 
1.1.3 Biological Transport 
After vitamin E ha<s been consumed, tocopherols are passively absorbed across the 
intestinal membrane and packaged into lipid constructs or complexes, called 
chylomicrons, that are composed of triglycerides and phospholipids. These chylomicrons 
are then deposited into the intestinal lymph fluid where they eventually enter the blood 
stream.S Here, the chylomicrons are broken up into chylomicron remnants via lipoprotein 
2 
lipase and are endocytotically taken up into liver cells via remnant-receptors.8•9 The 
remnants are then processed into very-low-density lipoproteins (VLDLs) within these 
hepatocytes (Figure 2).9 
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Figure 2. Molecular pathway of vitamin E in vivo9 
As mentioned previously, (RRR)-a-tocopherol is the vitamer that is most 
efficiently incorporated into the body and used in tissues.6 This evidence at first may 
seem confusing since the North American diet is dominated by y-tocopherol intake. 
Traber and Kayden have shown that the liver differentiates the vitamers and there is 
selectivity for a-tocopherol deposition in tissues.1O They demonstrated this by giving 
human volunteers a single dose of all-rac-a-tocopherol acetate or equivalent amounts of 
all-rac-a-tocopherol and (RRR)-y-tocopherol. lo Samples of bile and plasma lipoproteins 
were taken and analyzed for tocopherol content. High performance liquid 
3 
chromatography (HPLC) and fluorescence detection were used to quantify the relative 
amounts of a- and y-tocopherol. Two days after administration of these vitamin E pills, 
there wac;; a drastic decrease in the amount of y-tocopherol in the blood plasma in 
comparison to a-tocopherol. lO The opposite was observed when tocopherol quantities 
were determined from the bile samples retrieved from post-gall bladder surgery.lO 
Samples of bile were shown to have greater amounts of y-tocopherol in comparison to a-
tocopherol. 10 This evidence suggested that although both fonus of tocopherol are 
absorbed into the liver, here they are differentiated. a-Tocopherol is retained whereas 
non-a-tocopherols are excreted. 
1.1.4 a-Tocopherol Transfer Protein and Substrate Specificity 
Figure 2 shows the excretory pathw,ay of p-, y-, and o-tocopherol after leaving the 
liver. They are either excreted into the bile or degraded into carboxyethyl 
hydroxychroman (CEHC) metabolites that are removed from the body through urine.9 A 
transfer protein found in liver cells selectively retains a-tocopherol. This protein is called 
a-tocopherol transfer protein (a-TIP) and it assists in the secretion of a-tocopherol into 
VLDLs.9 
a-TIP binds to a -tocopherol selectively over p-, y-, and o-tocopherol and to the 
2-(R) isomer over the 2-(S) isomer. 11.12 Deuterated samples of (RRR)-a-tocopherol and 
(SRR)-a-tocopherol have demonstrated this stereospecificity of a-TIP. 10 Twenty-four 
hours after patients were administered either one of these compounds, a greater amount 
of the (RRR)-stereoisomer was present in the blood plasma, indicating a preference of 
having position 2 as the (R)-stereocentre. 13 
4 
The substrate binding site of a-TIP is structured in such a way to accommodate a 
fully methylated chromanol and an (R)-stereocentre at position 2 (Figure 3).8 These 
conditions make it optimal for binding and stabilization to occur with (RRR)-a-
tocopherol. 8 Studies to determine the interactions between a-TIP and the other vitamers 
have shown a decrease in affinities because fewer protein-substrate interactions occur 
within the binding site. (RRR)-y-Tocopherol has a 10-fold decreal)e in affinity since it 
lacks a methyl group at position 5 whereas (RRR)-8-tocopherol binds even more poorly 
(50-fold less) because it lacks two methyl groups at positions 5 and 7.8 
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Figure 3. Atom-residue interaction between a-TIP and a-tocopherol (internal water 
molecules all black balls) 14 
The two remaining stereocentres of tocopherol (i.e. positions 4' and 8') do not 
play an important role in binding affinity mainly because of the great flexibility of the 
isoprenoid taiJ.14 Crystal structure analysis shows that the phytyl tail of a-tocopherol is 
curved when bound to a_Tfp.14 
1.1.5 Antioxidant Properties 
The main biological function of vitamin E is to inhibit the peroxidation of 
membrane phospholipids (Figure 4).2 Although the superoxide anion (02--) hal) the 
5 
HO 
·HX 
HO 
reductant 
Figure 4. Peroxyl radical fonnation and tennination in lipid membrane15 
strength to oxidize lipids, it is too polar to enter the bilayer. Its protonated fonn, the 
perhydroxyl radical (OOH), does have the ability to react with the lipids within the 
membrane, however. 16,17 
Another reactive oxygen species that causes lipid peroxidation is the hydroxyl 
radical ("OH).14 Having a reduction potential of over 2300 millivolts, this species 
oxidizes anything that is susceptible to hydrogen abstraction. These radicals are usually 
generated from the homolytic cleavage of hydrogen peroxide (H20 2) by metal ions (e.g. 
Fe2+).15 Despite being considered the most important reactive oxygen species in the 
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initiation of lipid peroxidation, these radicals are too unstable and dimerize within 
d 16 nanosecon s. 
Peroxynitrite (ONOO-) is another known oxidant that initiates lipid 
peroxidation. 18 It is spontaneOUSly fonned when nitric oxide (NO) and superoxide are 
within a few cell diameters of each other. 19 As the acid (i.e. ONOOH), it is homolytically 
cleaved, supplying membrane phospholipids with the hydroxyl (OH) and nitrogen 
dioxide (N02) radicals.2o 
The tirst step of lipid peroxidation, which is also the rate-limiting step, is the 
fonnation of the carbon-centred radica1.3,15 Polyunsaturated fatty acids (PUFAs) possess 
a characteristic l,4-pentadiene system that is susceptible to hydrogen atom abstraction.3,15 
The pentadienyl radical rearranges to fonn the more stable conjugated diene and reacts 
readily with an oxygen molecule to fonn a peroxyl radical (~O, = 1000 mY), an oxidant 
that is more potent than the simple alkyl radical (~EO' = 600 m V).15 
In the presence of tocopherol, the peroxyl radical comes in close proximity so that 
the molecules' electron clouds overlap and the transfer of the phenolic hydrogen atom to 
the lipid is allowed, generating a lipid hydroperoxide and a tocopheroxyl radica1.3 The 
propagation of the radical onto a-tocopherol is favoured because the tocopheroxyl radical 
is delocalized on the aromatic ring (Figure 5).3 
The tocopheroxyl radical can be terminated in either one of two general ways. 
The first way is that it can couple to another peroxyl radical (OOL) to generate a non-
radical adduct. 3 If termination occurs by this route, then each molecule of tocopherol has 
the capability of reducing two lipid peroxyl radicals, but is not regenerated.3 The other 
way that the tocopheroxyl radical is tenninated is by water-soluble reductants, such as 
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Figure 5. Resonance fonns of a-tocopheroxyl radical and its termination by adduct 
fonnation with peroxyl radical3 
ascorbate (vitamin C), glutathione, or thiols, a~ illustrated in Figure 4.6 A molecule of 
tocopherol is regenerated and can continue to inhibit lipid peroxidation.6 Without the 
tennination of lipid peroxide species, the membrane would become damaged and a series 
of other biological responses soon take effect. These responses include the induction of 
II . 21 hI' 22 d d . d' 23 ce . apoptoslS, at erosc erosls, an neuro egeneratlve Iseases. 
1.2 The Dipyrrornetheneboron Difluoride Fluorophore 
1.2.1 Discovery and Core Structure 
The first reported synthesis of a dipyrrometheneboron difluoride (BODIPY) entity 
was by Alfred Treibs and Franz-Heinrich Kreuzer in 1968.24 It was not until two decades 
later, however, that the application of BODIPY to biology was realized. Since its 
discovery, the fluorophore has been introduced into probes for use in both aqueous 
media25 and in cell membranes.26 The main commercial supplier for BODIPY labels is 
Invitrogen/Molecular Probes, Inc. (Burlington, ON). The available quantities are not 
realistic for use as reagents in bioorganic synthesis, however.27 Instead, chemists often 
resort to building their own fluorophores. 
The conventional name for BODIPY is dipyrrometheneboron difluoride but it has 
also been given the IUPAC name 4-bora-3a,4a-diaza-s-indacene, based on the indacene 
8 
skeleton?S For the purpose of this paper, it will simply be refelTed to as BODIPY or the 
further abbreviated BDP. The numbering system of BODIPY and its dipyrromethene 
synthetic precursor is written in Figure 6 (Notice how BODIPY and dipyrromethene do 
not follow the same numbering system). 
7 5 3 
8~2 '-~H ~J 
9 11 10 1 
III 
Figure 6. (I) Indacene; (II) BODIPY core; (III) dipyrromethene 
1.2.2 Fundamental Properties 
BODIPY is widely used in the research of biomolecules because of its high 
photostability, large extinction coefficient (90 000 M-1cm- I ), high quantum yield (0.9), 
and negligible triplet state formation. 28,29 It is also relatively compact in size and low in 
polarity (electronically neutral).3o The lipophilicity of BODIPY readily allows entry into 
cell membranes and other greasy environments such as plasma lipoproteins.31 ,32 Another 
key feature of BODIPY is its large spectral overlap as a result of a small Stokes shift.25,33 
This large overlap brings forth a challenge as light scattering can interfere with the 
signal.34 
At low concentrations, fatty acid analogues possessing the BODIPY unit retain 
key properties such as green fluorescence (- 500 nm), high quantum yield, and 
insensitivity towards environment.35 The typical green fluorescence is a result of a strong 
S07S1 transition. This dye also appears to fluoresce at a shorter wavelength (- 375 nm) 
because of a S07S2 transition that is twenty times weaker in intensity.3o At higher 
concentrations, BODIPY dyes have the ability to fonn dimers (or 'excimers') in 
membranes. These excimers are spectrally different from the parent dye, emitting 
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anywhere from green to red wavelengths.36 For example, the phosphatidylcholine probe 
C4-BDP-C9-PC begins to show increasing fluorescence depolarization and self-quenching 
at equivalents 1 :500 mol:mol or greater with respect to dioleoyl phosphatidylcholine 
(DOPC).35 Ceramide and PC conjugates of BODIPY have both shown shifts from green 
to red emission, likely due to this excimer fonnation. 35,37 
1.2.3 Previous Applications of BODIPY to Biology 
Radiolabelled and fluorescent analogues of lipids have been used extensively to 
study the behaviour of natural compounds. BODIPY has been incorporated into studies 
involving nucleic acids and proteins, as well as various lipids (e.g. fatty acids,38 
triglycerides,39 phospholipids,40,41 and cholesteroI42). 
Fluorescent analogues of lactosylceramide 1 (Figure 7) have enabled chemists to 
monitor how this glycosphingolipid undergoes endocytosis within different cell types by 
fluorescence microscopy.29 The linker separating the glycosphingolipid from BODIPY is 
an all-methylene chain ([CH2]n) that does not pose any unwanted polarity, ideal for lipid 
probes.29 At low temperatures, the determination of its location becomes apparent 
. d' I af d . 29 Imme tate y ter en OCytOSIS. Analogues 2 and 3 of sphingosine (Figure 7), a 
metabolite of ceramide, represent another example of BODIPY -sphingolipid analogues 
that are useful for biophysical and biochemical analyses.43 
For the analysis of the distribution and transportation of cholesterol in 
membranes, several fluorescent analogues have been prepared but most were not highly 
fluorescent, were photolabile, or did bear a strong structural resemblance to cholesterol.44 
Tritiated and carbon-14-labelled sterols have been implemented in studies in the past but 
trends in lipid research are now moving away from radiolabelling and instead towards 
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Figure 7. Recent examples of lipid analogues possessing BODIPY 
fluorescence. Of the fluorescent analogues of cholesterol synthesized before a couple of 
years ago, none have displayed a similar behaviour to cholesterol in membranes.45 
Recently, several fluorescent analogues of cholesterol bearing the BODIPY group were 
synthesized.42,46 Compound 4 (Figure 7) was found to mimic the properties of 
cholesterol whereas analogues that contained polar groups such as an ester linkage in the 
linker between the sterol and the fluorophore did not serve as faithful mimics of 
cholesterol. 44,47 ,48 
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An emerging role of BODIPY is its use in detecting oxidative stress and 
identifying antioxidants that exist in membranes (e.g. vitamin E analogue 5; Figure 7). 
As these antioxidants inhibit free-radical chain peroxidation of PUFAs, fluorescence 
activity may increa~e or decrease depending on the dye that is incorporated. BODIPY 
has been shown to undergo fluorescence quenching both chemicalll9 and 
photophysically5o.51 in the presence of radicals. This property enables the use of these 
probes to measure lipid peroxidation both in vitro and in vivo. The ability to suppress in 
fluorescence was applied more recently in the study of vitamin E' s antioxidant 
properties. 52 
1.2.4 Synthesis of the Dipyrromethene Skeleton 
In the presence of acids, pyrrole goes through an Ehrlich-type condensation with 
pyrrole-2-carboxaldehyde to form a dipyrromethene (Figure 8).43 This type of reaction 
may also be referred to as the MacDonald coupling, a tenn commonly used amongst 
porphyrin chemists.53•54 Dipyrromethenes can be found a~ molecular subunits in nature. 
They are rings Band C that form biliverdin, a bile pigment, and two dipyrromethenes 
form one porphyrin, the large metal-chelating macrocycle that is found in chloropla~ts 
and red blood cells.55 Depending on the substituents on the ring, these pyrrole-2-
carboxaldehydes may be available commercially or they can be easily synthesized by the 
Vilsmeier-Haack reaction.56 
During this condensation, pyrrole has enough nucleophilicity to attack the 
aldehyde in the presence of an acid, losing a molecule of water.55 These two-component 
reactions are done with equimolar amounts of each pyrrole. No step for oxidation of the 
aromatic system is needed since the condensation directly forms the dipyrromethene. 
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Figure 8. General two-component synthetic route to dipyrromethenes 
This two-component route offers a convenient method to produce BODIPY molecules 
that are unsymmetrical and/or unsubstituted at the meso-position.28,57 
Suitable acids for this condensation include hydrogen halides (e.g. HBr), metal 
salts used typically for Friedel-Crafts reactions (e.g. ZnCh), and non-metallic Lewis acids 
(e.g. POCh). The dipyrromethenium ion that is produced is combined with the anion of 
whatever acid was used (i.e. Br-, cr, P02Ch-).58 Boron trifluoride diethyl etherate can 
act as a Lewis acid to assist in this condensation in addition to forming the BF2 bridge. 
This would be a very convenient one-pot synthesis of BODIPY directly from pyrrole.58 
A limitation to this condensation is that the pyrrole nucleophiJe must not react in 
excess since the dipyrromethenium salt formed is much more electrophilic than the 
pyrrole-2-carboxaldehyde precursor. 55 Most of the time, these salts tend to precipitate 
out of solution so the formation of these tripyrromethenes is limited. 
The dipyrromethenium salts may be treated with bases (e.g. Ca(OH)2 in pentane) 
to liberate the neutral dipyrromethene. These free-bases are less stable than their 
protonated forms, especially with minimal substituents (i.e. less than three alkyl groups), 
and may still be susceptible towards nucleophilic attack. 33,55 For example, an 
unsubstituted dipyrromethene molecule has been synthesized but decomposition is 
reported to occur at temperatures as low as -40 0c.55 The stability of the 
dipyrromethenium salts increases as the number of substituents along the backbone 
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increases.57 Despite this great instability, several groups have recently prepared the 
BODIPY core without any substituents.59,6o 
The three-component approach towards the synthesis of BODIPY produces 
dipyrromethane as an intermediate, as opposed to the further oxidized dipyrromethene. 
Dipyrromethanes are much more stable species than dipyrromethenes as long as they are 
in purified form. Dipyrromethanes are stored at 0 DC in the absence of light without any 
reported decomposition.61 In order to convert dipyrromethanes into the required 
dipyrromethenes, an oxidant such as 2,3-dichloro-S,6-dicyanoquinone (DDQ) or p-
chloranil is required, the latter of which is preferred because of its milder reactivity and 
eac;ier control.53 
Rl R, Rl Rz 
H HN 
R N HX oxidant 2Xl~ R.CHO R, R3 
Rl Rl 
Rz ' R3 
Rz R3 R2 R3 
Figure 9. General three-component synthetic route to dipyrromethenes 
Three separate molecules are used to form dipyrromethane by this three-
component route in a one-pot reaction (Figure 9).42 The ability to incorporate a wide 
variety of aldehydes allows a quick and simple way of synthesizing symmetrical 
BODIPY dyes with great diversity at the meso-position. Anhydrides may be used in 
place of aldehydes with the advantage that a carboxylic acid is generated, which can be 
used for further conjugation.57,62 The yields from this three-component route are 
generally much lower than the two-component alternative because there is a greater 
chance of by-product formation.42,63 
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During the synthesis of dipyrromethanes, thin layer chromatography (TLC) often 
shows a small amount (less than 5%) of material tailing from the product spot and a third 
component that remains on the baseline. 1H NMR spectra indicated that the tailing spot 
is the tripyrromethane formed during condensation. Tripyrromethanes appear to be less 
stable than dipyrromethanes. They begin as a white solid but decompose to a black 
substance in less than a day at room temperature. 61 
As opposed to using aldehydes or anhydrides, acyl chlorides tend to give higher 
yields since it produces the dipyrromethene directly without any required oxidation.64 
Electron-withdrawing groups on acyl chlorides help increase the rate of the 
condensation.63 Depending on the acyl chloride chosen, this route continues to allow the 
synthesis of many different meso-substituted BODIPY derivatives.65,66 
Oligomers and porphyrinogens may form instead of dipyrromethanes if the 
pyrrole reactants lack appropriate substitution at the a-position (Figure 10). 
Regioselectivity also becomes an issue since both a-positions on the pyrrole are 
reactive.28 This can also be applied to inappropriately substituted dipyrromethenes 
following the two-component route. At these extremely reactive positions, there is 
Both (L·positions 
capable of 
nucleophilic attack 
Unsubstituted positions enable further 
condensation resulting in oligomers or 
porphyrinogen synthesis 
( 
, R2 R, 
R, 
R2 - __ Oligomers and/or 
___ porphyrinogens 
R2 ) 
----y 
lack of regioselectivity 
Figure 10. Oligomerization and porphyrinogen synthesis from lack of appropriate 
substitution of pyrrole reactants 
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nothing preventing an electrophilic attack.57 In order to exclusively obtain 
dipyrromethanes, the pyrrole should be in excess (40) 1) and can therefore act as solvent 
as well during the condensation.61 
The extreme difficulty to form non-a-substituted BODIPY molecules has been 
noted in literature (Figure 11).57 To maintain the molecular linearity of a probe 
incorporating BODIPY, substituents at positions 2 and 6 are not possible without at least 
methyl groups at the a-positions as placeholders. However, probes substituted at 
positions 3 and 5 suffer from the molecular bend that is created at the point where the 
fluorophore and the rest of the molecule are joined. 
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Figure 11. Synthetic limitations of BODIPy57 
1.2.5 Conformational Analysis of Dipyrromethenes 
8 
not reported 
In order to complete the formation of the BODIPY fluorophore, it is important to 
assess whether the dipyrromethene backbone is in the (E)- or (Z)-confonnation. An 
earlier study of the conformation of dipyrromethenes was done in 1975.67 They 
specifically looked at the possibility of both (E)- and (Z)-configurations of the exocyclic 
double bond on 3,4-dimethyl-5-(1H)-2,2'-pyrromethenone (Figure 12). These 
hydroxypyrromethenes (Le. the tautomer of the pyrromethenone) are biologically 
important because they are the building blocks to many bile pigments, such as bilirubin.68 
To determine the configuration of the double bond, lanthanide shift and nuclear 
Overhauser effect (nOe) experiments were conducted. Fa1k et a1. reported that both (E)-
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Figure 12. (Z)- and (E)-configurations of 3,4-dimethyl-5-( IH)-2,2' -pyrromethenone 
and (Z)-configurations of the hydroxypyrromethenes were present.67 Even though the 
hydroxypyrromethene can be viewed as a derivative of dipyrromethene, there is enough 
difference in electronics and structure that makes them poor candidates for comparison 
with other dipyrromethenes.55 
Another study on the conformation of dipyrromethenes was published in 1977.55 
As the free-base, it was determined that dipyrromethenes must possess a hydrogen bridge 
in the ground state that is shared between both pyrrole nitrogens.69 The question of 
whether or not this bridge directs the configuration of the exocyclic double bond was 
explored using N-CH3, furyl, and thienyl derivatives, which would not display such an 
interaction.55 The configuration of the double bond in 3',5'-dimethylpyrromethene (N-H 
analogue) and N-3',5'-trimethylpyrromethene (N-CH3 analogue) was studied by nOe 
experiments. It was found that even without this hydrogen bridge, the N-CH3 analogue 
preferred to form in the (Z)-conformation. Only under photochemical conditions did E-Z 
isomerization occur (Figure 13).55 (E)-Dipyrromethenes make up the cyanine dyes, 
which have strong fluorescence with emission at 600 nm and an extinction coefficient 
value of 100 000 M-1cm- 1 or greater.70 The isomerization of cyanine dyes under 
photoexcitation would make these dyes unsuitable choices in the synthesis of fluorescent 
probes.3o 
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Figure 13. Photochemical E-Z isomerization of N-CH3 dipyrromethenes 
With the N-H analogue where the hydrogen bridge is present, the exocyc1ic 
double bond remained in the (Z)-configuration, even upon attempted photoinduction 
(Figure 14)_55 BODIPY can be considered as stabilized cyanine dyes with the BF2 bridge 
locking the backbone in this syn conformation. Without the ability of the dipyrromethene 
backbone showing selectivity towards this cis formation, non-reactive by-products would 
form and complicate the synthesis of BODIPY. 
Ehrlich-type 
condensation 
H-bndg~ fj 
H N 
I 
N 
/ \ 
H 
I 
N 
1# 
Figure 14. Hydrogen bridge stabilization of N-H dipyrromethenes 
1.2.6 Synthesis of BODIPY: Addition of the BF 2 Bridge 
Dipyrromethenes can be both protonated (e.g. during condensation) as the stable 
salt and deprotonated as the anionic ligand that chelates metals. Different alkali earth 
metal complexes have been shown to be too unstable and tend to form 
bis(dipyrromethene) complexes, except for the monovalent BF2 pseudometa1.33,71 ,n The 
BF2 bridge can be added to the dipyrromethene backbone in the presence of an organic 
base such as triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA) (Figure 15).33 
Once the BF2 bridge has been formed, the molecule (i.e. BODIPY) becomes much 
more stable than the dipyrromethene precursor, showing no observable sensitivity 
towards light unlike so many other fluorophores?3 BODIPY is stable to silica gel 
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Figure 15. Last step in synthesis of BODIPY 
chromatography and can be easily purified by recrystallization.58 Another difference 
between BODIPY and its dipyrromethene precursor is that BODIPY has two highly 
delocalized resonance forms whereas the dipyrromethene has two electronic structures 
that are in tautomeric equilibrium (Figure 16).33 
Figure 16. Different 1t-system~ for BODIPY and dipyrromethene33 
An interesting pattern seen by various substituted BODIPY analogues has shown 
that substituents at positions 2 and 6 can reduce the quantum yield (<I» up to half of its 
original value.33 Substitution at the meso-position appears not to affect the wavelength 
for excitation or emission. 57 The quantum yield drops significantly with various aryl 
substituents at this position as well. In order to increa",e the quantum yield, BODIPY 
analogues should possess methyl groups at positions 1 and 7 (compound 10; Figure 17), 
, 
~ N, /N".. 
B 
I \ 
F F 
9 10 
+ = 0.36 (OCM) cp = 0.94 (OCM) 
Figure 17. meso-Substitution and its effect on quantum yield 
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or the bulkiness of the meso-aryl group should increase, which reduces free-rotation and 
further locks the aryl group into an orthogonal conformation.57,64 
1.2.7 Extending the Conjugation of BODIPY 
The 1t-electrons are delocalized along the dipyrromethene backbone of BODIPY. 
Extension of this conjugation with appropriate substituents on the pyrrole rings is used in 
designing probes that are tailored to photoexcite at selected wavelengths.28 As stated 
previously, substitution at the meso-position does not greatly affect the wavelength at 
which the fluorophore is excited or emits. A much more effective way of changing these 
values is by substitution at the a-positions.73,74 In order to synthesize such analogues, 
pyrrole precursors with the appropriate substitutions are required since this chemistry 
usually cannot be done after the formation of BODIPY. 
A bathochromic shift occurs when substituents are added to the BODIPY core 
that results in excitation and emission at longer wavelengths. Substituents that produce 
bathochromic shifts include alkenyl, dienyl, trienyI, and heteroaryl groups (e.g. pyrryl, 
thienyl, furyI, etc.). For example, when the conjugation of BODIPY is extended by a 
thienyl group, the excitation wavelength shifts to 558 nm and the emission wavelength 
shifts to 568 nm.58 
1.3 Introduction of a BODIPY -Tocopherol Conjugate 
Unlike nitrobenzoxadiazole (NBD), dansyl (DAN) and anthroyloxy (AO) 
fluorophores that are linked to molecules with bridges containing heteroatoms (i.e. 0 
from esters and N from amines or amides), BODIPY analogues can possess an all-
methylene linker that would maximize the lipophilicity of the probe. The addition of 
these heteroatoms may alter the way the probe packs into membranes because of an 
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added polarity in a lipophilic environment (see BODIPY-cholesterol; Section 1.2.3). The 
fluorescence quantum yield of BODIPY is two to three times greater than NBD; its 
extinction coefficient is approximately four to five times greater (Table 1)?5 
Table 1. Spectroscopic comparison of fluorophores BODIPY and NBD35 
Fluorophore BODIPY NBD 
Quantum yielcf 0.9 0.3 
E(M1cm-1l 90000 20000 
ain ethanol at 25°C 
NBD (460-480 nm) has been used in the development lipid probes75 but its 
sensitivity to environment, polarity, photobleaching and tendency to self-quench have 
made researchers seek alternatives.76 Through ionization and fluorescent quenching 
measurements,77,78 membrane probes (e.g. fatty acids) that contain NBD are reported to 
possess extreme curvature in the alkyl chain. This is because of a physical interaction 
between the fluorophore and the polar head groups of the phospholipids (Figure 18). In 
HO 
o 
Figure 18. Location of NBD in cholesterol and PC analogues 75 
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the design of synthetic probes, one seeks to prepare analogues that are of similar physical 
length as the original molecule and, particularly with membrane probes, that they occupy 
a similar volume of space. For example, the saturated fatty acyl chains of PC are 
relatively linear and point towards the centre of the bilayer. In contrast, NBD-PC has a 
curve in its methylene chain, resulting in a molecule that occupies a greater volume 
within the membrane (Figure 18). 
A series of fluorescent analogues of vitamin E were prepared previously by our 
group with the intention of probing the localization and trafficking of vitamin E (Figure 
19). Binding studies to u-TTP showed that only analogues from the NBD (Ud) and AO 
(12d) series bound specifically and reversibly with dissociation constants, Kd, of 60 and 
280 nM, respectively.79 The extreme bulkiness of the AO fluorophore and its orthogonal 
attachment to the chain makes it a poor analogue for future use as a probe. With C9-
NBD-u-Toe Ud, significant spontaneous membrane transfer is observed. Intervesicular 
transfer between membranes is not uncommon amongst NBD-probes for this has been 
reported previously with NBD_PC.80 Because of these similarities with the other NBD-
lipid analogues, it was also postulated that C9-NBD-u- Toc Ud must have some 
HO 
HO 
~"'" N02 
n N \ ""N H II I 
N-O 
,o)-Nilrobenzoxadiazole-<x -tocopherols 
(NBD)-<!-Toc 11a-<l (n = 1-4) 
O-ygo "P I 
N/ "'" N/ in H I I 
#' 
,o-Dansyl-<t-tocopherols 
(DAN)-u-Toc 13a-<l (n = 1-4) 
HO 
,o-An1hroyloxy-<x-tocopherols 
(AO)-fl-Toc 12a-<l (n = 1-4) 
~~ 
'-NN 
,o-N-Methytanlhraniiamide-a-tocopherols H 
(NMA)-Cl-Toc 14a-<l (n = 1-4) 
Figure 19. Fluorescent analogues of vitamin E for localization studies 
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curvature in the methylene chain because of an interaction of NBD with the polar 
phospholipid heads. 
It should be expected that synthetic analogues differing structurally from intrinsic 
lipids bind with less affinity to target proteins and may have some degree of perturbation 
within membranes.44 Recent work in our group has shown that our leading fluorescent 
vitamin E analogue, C9-NBD-a-Toc ltd, is more similar to a-tocopherol than the other 
tocopherols in terms of the physical attributes within the membrane. This was assessed 
using differential scanning calorimetry. 81 Some factors to consider when designing 
probes include size, volume, hydrophobicity, and charge distribution. Using molecular 
modeling software (e.g. Spartan), it is possible to determine the approximate length of 
molecules following simple molecular mechanics energy minimization. A comparison of 
molecular length between a-tocopherol, C9-NBD-a-Toc ltd, and a BODIPY-tocopherol 
conjugate (BDP-a-Toc), which is separated by a seven-carbon bridge, is shown in Figure 
20. 
(A); 20.91 ~ \ . t --
I I -tr\-\--' ,.\ 
Figure 20. Molecular comparison of a-tocopherol (A), C9-NBD-a-Toc (B), and C7-
BDP-a-Toc (C) [Red arrows indicate atoms used for calculating molecular length] 
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The high quantum yield of BDP-a-Toc allows one to use low concentrations, 
which may possibly reduce any negative impact on the membrane or protein receptor. 
Another factor to consider in the design of fluorescent probes is that there is little spectral 
overlap between the probe and endogenous chromophores, such as aromatic amino 
acids.30 The incorporation of f1uorophores that enable detection at longer wavelengths 
(e.g. BODIPY) reduces the interference of any cellular autofluorescence.82 
1.4 Project Overview 
This thesis will entail the synthesis of C7-BDP-a-Toc (Figure 20; C). The choice 
of having seven carbons in the bridge is ba'}ed on the molecular length of C7 -BDP-a-Toc 
(22.9 A), which is very similar to that in leading probe C9-NBP-a-Toc (22.5 A). Once 
made, this analogue will be tested for its binding affinity to a-TIP. In order to examine 
the effect of molecular length on binding to a-TIP, C6- (21.6 A) and C8-bridged (23.7 
A) analogues will be synthesized as well. 
The key step to the synthesis of these analogues is a cross-metathesis reaction 
inspired by the work of Nussbaumer et al. who linked functionalized BODIPY 
intermediates to the sphingosine pharmacophore by this reaction.43 Vinyl Trolox can be 
derived from the commercially available (S)-Trolox and alkenylBODIPYs can be 
synthesized from (J}-alkenoic acids (Scheme 1). 
~C02H 
II 
KEY STEP: 
olefin 
metathesis 
Scheme 1. Synthesis of BDP-a-Toc analogues 
TBSO 
HO 
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In addition to the synthesis of these molecules, another analogue whose 
fluorophore conjugation is extended by a thienyl group (TBDP-a-Toc) will be made. 5-
(2'-Thienyl)pyrrole-2-carboxaldehyde, which can be made by Suzuki-Miyaura cross-
coupling83 followed by formylation,84 will be required for building the new f1uorophore 
(Scheme 2). BDP-a-Toc can be paired with this thienyl derivative to observe if liver 
cells pool vitamin E when given in excess. 
~S 
C(s Suzuki-Miyaura ~ followed by TBSO Viismeier·Haack B(OH), # B, in 
Boc-Nb 
KEY STEP: 
olefin 
OHC metathesis 
11 11 
~~ HO # 0; #~ 
• 
Scheme 2. Synthesis ofTBDP-a-Toc analogues 
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2 RESULTS AND DISCUSSION 
2.1 Original Design and Synthetic Attempts of BDP-a-Toc 
During the planning phase of this project, the original target molecule 15 
possessed a BODIPY fluorophore that was monoalkylated at position 2 (Figure 21). The 
intention behind this design was that the fluorophore should remain relatively linear with 
the rest of the molecule, unlike the AO-a-Tocs 12a-d that possessed the undesirable 
orthogonal attachment, which made them poor binders to a-TIP. 
Figure 21. Original design of the BDP-a-Toc target molecule 
This project wa-, the first time that the synthesis of a fluorophore itself was 
needed. Previous syntheses of fluorescent a-tocopherol analogues in the Atkinson 
laboratory had used commercially available, pre-formed fluorophores that coupled to 
alcohols or amines.79 The BDP-a-Tocs have been designed however to possess an all-
methylene chain, which maximizes lipophilicity. Unlike the projects before, this meant 
having to prepare the fluorophore itself, which included extensive pyrrole chemistry. 
Although pyrroles are able to undergo substitution at all five positions, they are 
challenging molecules to make because of poor control over regiochemistry.85 
Of the very few papers that discuss alkylations or couplings to an intact BODIPY 
fluorophore, the one that was most attractive and seemingly most suitable for this project 
was the work of Wim Dehaen.86 A novel way of functionalizing the BODIPY ring after 
it is a-,sembled is exemplified in fluorophore 16 (Scheme 3). The chemistry of 16 has 
been likened to imidoyl chloride87 and therefore cross-couplings, such as Suzuki or Heck, 
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(a) 
"""" '\ 
\ N, /N~ 
a 
'\ 
\ N'a/N"", 
cf FI 'F CI R1 F' 'F R2 
16 17 (R, = CI) or 18 
Scheme 3. Reported cross-couplings using 3,5-dichloroBODIPy86 
were done.86 Other cross-coupling methods reportedly used on this molecule include 
Stille and Sonogashira.86 
Of these coupling reactions, Suzuki would be most applicable to our target 
molecule because it can be done using sp3-alkylboronic acids producing intermediate 
21a-c (Scheme 4), which only requires a desilylation to obtain the final compound. To 
perform a Suzuki cross-coupling for this reaction, the synthesis of a tocopherylboronic 
acid and a 2-chloroBODIPY fluorophore is needed (Scheme 4). 
r850 
TBsa 
\ n B(OH), Pd(PPI1,), 
19a-c (n = 1-3) 
21a-c (n = '-3) 
Scheme 4. Proposed Suzuki cross-coupling in synthesis of BDP-a-Toc 
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Unfortunately, there is no way to exclusively synthesize 4-chloro-2-
formylpyrrole, which would be needed to produce a 2-chloroBODIPY fluorophore, 
without generating a mixture of regioisomers. However, 5-chloro-2-formylpyrrole by-
product could also give a second target fluorophore, 3-chloroBODIPY. The synthesis of 
2- and 3-bromoBODIPY should also be considered because they may provide a greater 
reactivity if the BODIPY chlorides fail. 
Because pyrroles undergo electrophilic aromatic substitution with poor 
regioselectivity, most procedures for halogenation result in isomers that are difficult to 
separate. To selectively synthesize 23, Vilsmeier-Haack formylation on 2-chloropyrrole 
has been done previously,88 but 2-halopyrroles are poorly characterized because they are 
very unstable.88,89 2-Chloropyrrole decomposes to an unknown black material that 
remains solid up to temperatures as high as 700°C. Sublimation of this black material 
yields ammonium chloride crystals, a sign that the pyrrole ring hali broken apart.88 
The selective synthesis of 23 from N-Boc-succinanlidal 22 that avoids the 2-
chloropyrrole intermediate hall been reported. Under Vilsmeier-Haack conditions, 
succinamidals undergo dehydration to form 23 (Figure 22).90 When di-tert-butyl 
dicarbonate (BOC20) is used to protect the succinamidal, it stabilizes the molecule during 
this transformation and the yields are improved. Conveniently, this protecting group is 
M-- DMF, POe!3 J:)..:.!:!: ~ 
o N OH 0 N4' O~N) 
H H~ H 
~ I 
n _ n _ F\ 
el~N>--cHO el~N~ O~N/ 
H ' H N+e~ H 
23 ,/ " 
Figure 22. Suggested mechanism for the transformation of succinamidal to 5-chloro-2-
formylpyrrole under Vilsmeier-Haack conditions90 
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lost during the course of this reaction due to the acidic environment.9o 
Succinimide was ea'iily protected using di-tert-butyl dicmiJonate in good yields 
(Scheme 5). The next step required the slow addition of sodium borohydride to a stirring 
solution of 25 in tetrahydrofuraniethanoll:l. It is extremely important to add the hydride 
slowly and monitor the temperature of the reaction so that it does not rise above -50°C. 
The amidal does not form unless these two important details are followed. Once 
succinamidal 26 was made, it wa'i treated with phosphorus oxychloride and N,N-
dimethylfonnamide to make 23. Although this step was repeated several times, the yield 
(8%) remained much less than that reported in the literature (46%).90 
~O ~~~o, DMAP, o~o ~~~~~OH, .50 °C ~ 
ON N '0 N OH 
H 77% Soc 66% Soc 
~ ~ u 
8%![POCI3+DMFJ, 
DCE, oOC tort 
J:J---CI N CHO 
H 
23 
Scheme 5. Synthesis of 5-chloro-2-formylpyrrole from succinimide 
An alternative method for chlorinating pyrrole-2-carboxaldehyde uses tert-butyl 
hypochlorite prepared from bleach (i.e. NaOel) and tert-butano1.91 The preparation of 
tert-butyl hypochlorite is simple and straightforward. Bleach is cheap and readily 
available and the product is isolated with high purity.92 tert-Butyl hypochlorite is 
however reportedly less stable than the inorganic hypochlorite salts and decomposes 
under continuous exposure to light. The compound is stable for a few months when 
sto~ed in the freezer in the dark. 92 
29 
CI CI 0-- (CH3bCOCI28, J:J b h ~ ~ CCI • . a °C N CHO . CI N'>---CHO N/--CHO CI N CHO 
H H H H 
27 23 29 30 
26% 10% 11% 
Scheme 6. Chlorination of pyrrole-2-carboxaldehyde using tert-butyl hypochlorite 
The slow addition of this chlorinating agent to a solution of pyrrole-2-
carboxaldehyde in carbon tetrachloride on ice produced 29 (10%), 23 (26%), and 4,5-
dichloro-2-fonnylpyrrole 30 (11%). 23 has a different Rf on TLC 
(hexanes/tetrahydrofuran 15:1) than 29 and 30 so it can be easily removed by silica gel 
chromatography. With the partially purified 29/30 fraction, 29 was purified by 
recrystallization from hexanes/diethyl ether 1: 1 while 30 remained in solution. 
A general method for the bromination of pyrrole-2-carboxaldehyde uses 
molecular bromine (Scheme 7).93 Bromination at room temperature provided 4-bromo-2-
formylpyrrole 32 and 5-bromo-2-fonnylpyrrole 31 in a 6: 1-10: 1 ratio using this method. 
This is because the fonnyl group on pyrrole-2-carboxaldehyde directs halogenation with 
bromine to the 4-position. At higher temperatures, the proportion of 31 increases.93 To a 
solution of pyrrole-2-carboxaldehyde in carbon tetrachloride near reflux (70 °C) was 
slowly added a solution of bromine in the same solvent. From this reaction 32, 31, and 
4,5-dibromo-2-fonnylpyrrole 33 were produced with isolated yields 19%, 14%, and 14%, 
respectively. 
Br Br 
0-- Br2. Br--f')--cHo "0- Br~cHo CC'-,70OC N CHO . N CHO 
H H H H 
27 31 32 33 
14% 19% 14% 
Scheme 7. Bromination of pyrrole-2-carboxaldehyde using bromine 
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Silica gel chromatography using the unusual hexanes/tetrahydrofuran 15: 1 
mixture afforded partially purified samples of 32 and pyrrole-2-carboxaldehyde in one 
fraction and 31/33 in another. 32 was easily isolated by recrystallization from 
hexanes/diethyl ether 1: 1, but the separation of 31 and 33 by recrystallization was 
difficult. Instead, 31 was cleanly separated from 33 using sublimation (60°C at 0.5 
Torr). 
With chloropyrroles 29, 23, 30 and their bromo counterparts in possession, they 
could be condensed with pyrrole to form the dipyrromethene backbone of BODIPY. 
When hydrobromic acid was used, the dipyrromethenium salt often precipitated?6 This 
was not observed when 23 was condensed with pyrrole however (Scheme 8). Instead the 
reaction turned black and no precipitate was formed. This is understandable given that 
minimally substituted dipyrromethenes are unstable and only exist at very low 
temperatures (-40 °C).55 Attempts to carry out this same condensation at reduced 
temperatures also did not yield product. 
A common feature with many BODIPY fluorophores that lack meso-aryl groups 
is that they possess methyl groups at positions I and 3 on the same pyrrole ring. These 
R2 
R '~CHO 
H 
23; R, = CI. R2 = H 
30; R, = R2 = CI 
31 ; R, = Br. R2 = H 
33; R, = R2 = Br 
unstable 
2,4-dimethylpyrrole. HBr. f ~ j '~r BF3Et20.DBU. 
EtOH. OoC • R2 """" ~ '\ PhMe. 90 °C 
_ \\ • R2 
3249% NH HN~ 52-72% 
R, 
34; R, = CI. R2 = H 
35; R, = R2 = CI 
36; R, = Br. R2 = H 
37; R, = R2 = Br 
Scheme 8. Synthesis of BODIPY chlorides and bromides 
R, 
38; R, CI. R2 = H 
39; R, R2 = CI 
40; R, Br. R2 = H 
41 ; R, R2 = Br 
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methyl groups must be present to stabilize the dipyrromethene backbone during synthesis 
and therefore 2,4-dimethylpyrrole was used for the condensation. These alkyl groups 
, 
also have the added advantage of increasing lipophilicity, ideal for use as membrane 
probes.94 
When pyrrole was replaced with 2,4-dimethylpyrrole, bright red precipitates were 
rapidly formed and identified as the dipyrromethenium salts (Scheme 8). They were 
successfully prepared using 23, 30, 31, and 33 as electrophiles. It should be mentioned 
that these salts cause irritation on inhalation (particularly to nasal passages) and must be 
handled with extreme caution because they are relatively volatile.55 They were 
eventually transformed to the corresponding BODIPY derivatives using boron trifluoride 
diethyl etherate and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) without any 
complication. A summary of their photophysical properties is shown in Table 2 below. 
It is interesting to report that their extinction coefficients (c) are much less than the 
predicted value of 90 000 M-1cm-1•35 Halogens are more electron-donating than alkyl 
groups and lower these values. 
2 S fBODIPY h l"d 3841 Table . ipectroscoPlc companson 0 ales 
-
BODIPY halide Amax excitation (nml Amax emission (nmt e (M1cm-'l 
38 500 508 58000 
39 497 506 51000 
40 504 511 68000 
41 512 524 42000 
ain ethanol at 20°C 
Attempts to condense either 29 or 32 with 2,4-dimethylpyrrole did not produce 
the distinctly red precipitate that the other pyrroles did. Instead, these reactions turned 
black and no precipitate was observed. At the time, we were unaware of the problem 
with using non-a-substituted pyrroles to generate BODWY s. As mentioned in Section 
32 
1.2.4, oligomers and porphyrinogens form instead of dipyrromethanes if pyrroles lack the 
appropriate substitution. This is also apparently true with the synthesis of 
dipyrromethenes from the two-component route. Oligomers and porphyrins must have 
formed from the overly reactive a-position on 29 or 32. The inability to make either 2-
haloBODIPY changed the original design of the target molecule from a 2-substituted 
tluorophore, 15, to one that is linked at position 3 and hm; two methyl groups that provide 
stability (Figure 23). 
HO 
In 
428-<: (n = 1-3) 
Figure 23. New design of the BDP-a-Toc target molecule 
With the BODIPY halides now available for coupling, the attention was shifted 
towards making a tocopherylboronic acid. The proposed synthesis to obtain this 
intermediate is shown in Scheme 9. Trolox aldehyde can be generated from 
commercially available Trolox and has been used in the preparation of all of the other 
fluorescent analogues.79 Another inspiration for the design of the synthesis came from a 
paper reporting the synthesis of a novel class of prostaglandins.95 In this report, a 
phosphonium salt intermediate that also contained a pinacol-boronate was used. 
Racemic Trolox aldehyde was originally prepared because its precursor, rac-
Trolox, is less expensive and more easily available than optically pure (S)-Trolox. The 
synthesis of Wittig salt 46 began with the hydroboration of 6-bromo-l-hexene 43 by 
catecholborane. Intermediate 44 wa') rather unstable and blackened very ea')ily, likely 
from the oxidation and polymerization of 1,2-quinone. After Kugelrohr distillation, 44 
wa~ immediately subjected to transesterification with pinacol to the much more stable 
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Scheme 9. Attempted synthesis of a tocopherylboronic acid 
pinacol-boronate, 45. Following treatment with triphenylphosphine, Wittig salt 46 was 
generated. This salt is a thick sticky oil that remains stable if refrigerated.95 
After the Wittig reaction with rac-Trolox aldehyde 47, which was followed by 
catalytic hydrogenation, the last step to obtain tocopherylboronic acid was the removal of 
the pinacol ester of 49 (Scheme 9). There were concerns that acidic hydrolysis would 
also cleave the silyl ether and this prompted us to seek an alternative method. One 
seemingly efficient method was treating the ester with boron trichloride in 
dichloromethane.96 When this reagent was used, however, neither product nor starting 
material was recovered from the reaction. The one spot on TLC that seemed most likely 
to be product, which also gave the most mass, showed multiple Ar-CH3 signals on NMR 
and could not be further characterized by any other means. 
Since the removal of the ester of 49 failed, the other coupling methods from 
Dehaen's report86 were re-evaluated and it seemed that the Heck reaction should be the 
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next route to pursue (Scheme 10). The rationale behind this decision was that 
synthesizing the diene should be much easier than boronic acid 50 and it would allow us 
to see how the BODIPY halides reacted by cross-coupling. Heck conditions should 
preferentially react with the terminal alkene on 53 so there were no concerns with 
subjecting this diene to the coupling. Phosphonium salt 51 was easily prepared from 6-
bromo-I-hexene. The Wittig reaction with (S)-Trolox aldehyde 52 went in good yield 
(82%) to generate diene 53. 
PPh3, 
Br~ EtOH, reflux, BrPh3P~ 
43 99% 51 
TBSO 
820;.1(Sl-Trolox aldehyde 52, 
o LHMOS, THF 
53 
or 8; Rl ; CI N, ,N_ 
Pd(OAc)z, PPh3, TEA, DMF, 100 0* ~
Pd(PPh3l., TEA, DMF, 100 0 0; Rl ; Br R, ,\ 
TBSO ~ r; 
F-B-N 
# ~ 8 
54 \ ,; 
Scheme 10. Attempted Heck cross-coupling with BODIPY halides 38 and 40 
Attempts at the Heck cross-coupling of diene 53 with BODIPY chloride 38 and 
bromide 40 were performed using two different catalytic systems (Scheme 10), but with 
no success. After heating between 80 and 100°C and monitoring hourly, the reactions 
turned purplish black. It was shown by TLC that several product spots that weakly 
fluoresced were produced, but none were shown to be product by NMR (i.e, neither the 
aromatic proton signals nor the methyl groups of the fluorophore were present). Instead, 
these BODIPY halides were completely consumed by the reaction. Comparing our 
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BODIPY halides 38-41 to Dehaen's 16 led to the speculation that their meso-aryl group 
may be providing some stability to their fluorophore under these coupling conditions. 
There has been one other report on the failure of a palladium-catalyzed cross-
coupling in the presence of a BODIPY fluorophore, this time using the Sonogashira 
reaction (Scheme 11). Interestingly, fluorophore 55 also lacks a substituent at the meso-
position. Attempts at this reaction reportedly produced multiple products, as was 
observed with our Heck reaction, that also could not be characterized.46 
Elhynyl· TMS, ipr2NEI, 
Cui, Pd(PPhx THF, 60°C. 
Br \ 
TMS 
Scheme 11. Unsuccessful Sonogashira coupling of a BODIPY fluorophore lacking a 
meso-substituent46 
2.2 Generation of BDP-a-Toc by Olefin Metathesis 
After the unsuccessful attempts at cross-coupling using the BODIPY halides, 
alternative methods of conjugating the fluorophore to the chromanol were sought. A 
successful olefin metathesis of a BODIPY intermediate functionalized with a terminal 
olefin was reported (Scheme 12).43 The fluorophore, which lacked a meso-substituent 
and possessed two other methyl groups, is reportedly stable during this metathesis step 
i. Grubbs cal., 2nd gen. 59 
Ii. HClidioxane 
HO 
NH2 
n 
60 (n = 1 or 6) 
Scheme 12. Olefin metathesis step during the synthesis of BODIPY-sphingosine 
derivatives43 
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and does not intertere with the ruthenium catalyst. This key step is mild and easily 
controlled, requiring a gentle reflux in DCM at around 40 0c.43 
An initial concern with applying this method to our synthesis was the possibility 
that the chromanol would be too bulky to coordinate to Grubbs catalyst 59. A test 
reaction using vinyl Trolox 61 and two equivalents of I-hexene was successfully 
performed with a high yield of 89% (Scheme 13). The success of this test reaction 
prompted a new design in the synthesis of BDP-a-Toc. 
TBS00 BrPh3PCH3, LHMDS, TBSO~ 59,2 eq 1-hexene, I THF I oeM, 40 "C 
#' • #" #' 
o ~ CHO 88% 0 ~ 89% 
~ ~ 
TBSO 
Scheme 13. Test reaction for the metathesis of vinyl Trolox with I-hexene 
AlkenylBODIPYs 58a-c can be prepared from oo-alkenoic acids. If alkenoic acids 
are commercially unavailable or too expensive, they can be prepared by a Grignard 
reaction using the corresponding alkenylbromide and carbon dioxide gm; (C02). 7-
Octenoic acid 63 was prepared from 7-bromo-l-heptene. The carbon dioxide ga'3 that 
was produced from dry ice may not have fully dried as it was passed through the 
Drierite® drying tube, which would explain the low yield for this reaction. Other drying 
agents, such as calcium chloride, are used as alternatives. With the appropriate 00-
alkenoic acids available, ketopyrrole intermediates 65a-c were prepared (Scheme 14). 
Pyrroles readily undergo electrophilic aromatic substitution due to their electron-
richness. One of the ways to generate ketopyrroles is through Friedel-Craft acylation, 
which' requires a reactive acyl halide and a catalyst (e.g. AICh, FeBr3). There is often 
poor regioselectivity upon this acylation however, producing mixtures of 2- and 3-
37 
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n = 5: 98% 
°D ~S '>--N 
64a-c (n = 3-5) 
n = 3: gO%ilPYrrylMgCll 
n = 4: 97% 0 ' 
n = 5: 93% THF, -78 C 
° 
,,:P" in ~~ 
58a-c (n = 3-5) 65a-c (n = 3-5) 
Scheme 14. Synthesis of 2-ketopyrrole intermediates 
ketopyrroles.97 Direct alkylation of pyrrylmagnesium chloride with alkyl chlorides 
avoids having to reduce ketopyrroles by forming alkylpyrroles directly, but regioisomers 
are also produced.98 2-Ketopyrroles can be selectively obtained from the acylation of 
pyrrylmagnesium chloride with either acyl halides or esters (e.g. pyridyl thioates 64a-c; 
Scheme 14).98 Acylations with esters are more favourable because these reactions are 
less vigorous and less likely to form tars because of poor control.99 
Ketopyrroles are stable species that can be purified by chromatography. Before 
these intermediates can condense to form the corresponding dipyrromethenium salts, the 
carbonyl group must be reduced. Wolff-Kishner reduction is one method to reduce 
ketopyrroles. For example, acetylpyrrole is cleanly reduced to ethyl pyrrole by this 
method in 65% yield.99 
In the preparation of BODIPY -sphingosine 60, the ketopyrrole was reduced with 
sodium borohydride to yield the alkenylpyrrole.43 Following this method for preparing 
the BDP-a-Tocs, alkenylpyrroles 66a-c were synthesized with yields around 50% 
(Scheme 15). The purification of 66a-c was met with difficulty because these 
compounds decompose on the silica gel. They are also unstable in the presence of acid, 
even turning dark brown in the NMR tubes when dissolved in deuterated chloroform that 
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contains traces of acid. The purification method for these intermediates had to be 
changed to neutral alumina and all NMR spectra required either the neutralization of 
deuterated chloroform by passing through a basic alumina column or using the less acidic 
deuterated dichloromethane. NMR spectra of the alkenylpyrroles after neutral alumina 
chromatography were still crude so it was eventually decided that after reduction with 
sodium borohydride, the product would be simply flushed on a short alumina plug and 
then taken directly to the next step. 
~ 
658-<: (n = 3-5) 
NaBH4, 
iprOH, reflux. 
H 
OHC __ .(y 
~ , POCI3, ~~" DeM, 0 °C to rt ~ . 'n ~----------
66a-<: (n = 3-5) 
unstable 678-<: (n = 3-5) 
over 2 steps 
n = 3: 40% BF3E120, DIPEA, 
n = 4: 34% OOC 10 rt 
n=5:39% 
588-C (n = 3-5) 
j 
Scheme 15. Synthesis of alkenylBODIPYs 58a-c from ketopyrrole intermediates 
Initially, there were concerns about forming dipyrromethenium salts 67a-c with 
hydrobromic acid because of this newfound instability of alkenylpyrroles towards acids. 
Despite hydrobromic acid being used to condense the alkenylpyrroles in the methods 
described by Peters et aI. (and in a yield of 74%),43 multiple test reactions did not yield 
any precipitate. An alternative reagent that is used in making dipyrromethenes is 
phosphorus oxychloride.46 Replacing hydrobromic acid with phosphorus oxychloride 
generated 67a-c in situ. The reaction went from colourless to bright orange within 
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minutes after the addition of phosphorus oxychloride. Treating this solution with boron 
trifluoride diethyl etherate and DIPEA yielded alkenylBODIPYs 58a-c. 
The olefin metathesis between one equivalent of vinyl Trolox 61 and two 
equivalents of alkenylBODIPY 58a-c produced 68a-c with the yields varied from 48-
65% (Scheme 16). It is not too surprising to see yields that were lower than the test 
reaction with I-hexene from Scheme 13. The fluorophore increases the steric interaction 
with the catalyst, even at several methylenes away from the reactive alkene. Two 
equivalents of alkenylBODIPY were required because there is greater ease for the 
metathesis between two alkenylBODIPYs. This by-product is referred to as bisBODIPY 
and is easily removed by silica gel chromatography. We did not detect any bisTrolox 
formation from this reaction. 
TBS~O~ 
&" 0 l ,?" ,?" 
• 
61 n 
58a..: (n = 3-5) 
2 equivalents 
42a..: (n = 3-5) 
Grubbs Gil Cat. 59. TBSO 
DCM, 40oC 
n = 3: 65% 
n =4: 53% 
n = 5: 48% 
10% HCI in MaOH, 
,THF 
n = 3: 77% 
n = 4: 66% 
n =5: 74% 
Scheme 16. Completed synthesis ofBDP-a-Tocs 42a-c 
68a..: (n = 3-5) 
~ ~ ~: ;~~ H2, (Ph3PhRhCI, 
n = 5: 70% EtOH, 80 psi 
unoptimized 
69a..: (n = 3-5) 
The alkenylBODIPYs proceed through the metathesis with great stereoselectivity. 
The new alkene that is formed is mostly in the trans configuration (E/Z > 95/5).100 For 
the synthesis of BODIPY-sphingosine 60, this was important because the double bond is 
retained in the final compound.43 The synthesis of BDP-a-Tocs 42a-c requires the 
reduction of this alkene, however. 
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Double bonds are easily reduced using hydrogen gas and palladium on carbon 
(Pd/C) as catalyst. This has been the method of choice for reducing the alkene 
intermediates formed during the syntheses of fluorescent vitamin E analogues lla-d, 
12a-d, 13a-d, and 14a_d.79 There are also multiple reports that compounds possessing 
the BODIPY fluorophore react under these identical conditions without any reported 
decomposition. Such reactions include reduction of nitrophenyl groups to anilineslOl-l04 
and hydrogenolysis of benzyl groups. 105 
When alkenes 68a-c were treated with hydrogen gas and PdlC, the TLC showed 
rapid decomposition of the starting material within minutes. None of the desired product 
was ever retrieved from these reactions. Instead, an unknown and uncharacterizable 
transparent oil that gave a fluorescent blue spot on the TLC baseline had formed 
every time. These results conflicted with the published reports of high yielding reactions 
without decomposition. Correspondence with Professor Tetsuo Nagano of the University 
of Tokyo, lead author of several papers reporting such reactions, 102, 103, 105 provided the 
following unpublished information: 
"We have also got the results similar to those shown in your e-mail. 
Non-substituted BODIPY derivatives at 8-position often decomposed 
to unknown products by reduction of H2IPd-C immediately. " 
T. Nagano, 09/19/08 
Reduction of BODIPY 70 using hydrogen gas and Pd/C ha~ been reported to 
produce dipyrromethane 73 as a by-product with a yield of 7% (Scheme 17),53,106,107 but 
this occurred after days of continuous reduction (not within minutes as seen here). 
Perhaps the presence of a methyl group at the meso-position provides some partial 
stability during this reaction. With regards to the other reports of nitro-group 
reduction 101-104 and hydrogenolysis, 105 all of these fluorophores possessed meso-aryl 
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18% 
Scheme 17. Reduction of BODIPY to dipyrromethane by catalytic hydrogenation53,I06,lo7 
groups, which have been shown to greatly stabilize the backbone during synthesis. 
Catalytic transfer hydrogenation using organic molecules, such a..o;; diimide, has been 
implemented in the past to reduce alkenes as an altemati ve method. 108 The reduction of 
68a-c using potassium azodicarboxylate (PAD)109 however did not work, producing the 
same fluorescent blue spot on TLC instead. No starting material could be recovered by 
this method either. 
The final step in the synthesis of bile pigment nonylprodigiosin 75 also reported 
similar difficulties in reducing a double bond using hydrogen gas and PdlC (Scheme 
18),110 Attempts at this reaction led to complete destruction of the molecule. When 
Wilkinson's catalyst was used, the selective reduction of the alkene was achieved in good 
yield (i.e. 90%) without destruction of the dipyrromethene.11o The use of Wilkinson's 
MeO (Ph3P}JRhCl. MeO EtOH,l aim 
90% 
74 75 
Scheme 18. Reduction of cyclic nonylprodigiosin intermediate with Wilkinson's 
catal yst 11 0 
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catalyst was applied to BDP-a-Toc intermediates 68a-c (Scheme 16) with the assumption 
that the destruction of the fluorophore in the presence of hydrogen gas and PdlC is for the 
same reasons as 74. 
At 1 atm, no reaction occurred, but alkene 68a-c is likely less accessible to 
Wilkinson's catalyst than 74. Selective reduction of the alkene began at pressures of 40 
psi or greater. Decomposition of the BODIPY fluorophore was still observed but there 
was enough chemoselectivity to obtain 69a-c (Scheme 16). Increasing the concentration 
of the reaction in addition to further elevating the pressure provided even greater 
selectivity and higher yield. Currently, the best conditions for catalytic hydrogenation 
using Wilkinson's catalyst in ethanol is 80 psi for 28 h with an alkene concentration of 19 
mM, which the product in 70% yield. 
After the successful hydrogenation, the final step wa') the removal of the TBS 
group. One of the most common reagents for removing silyl protecting groups is 
tetrabutylammonium fluoride (TBAF). However, the BODIPY fluorophore decomposed 
with an obvious loss of fluorescence by TLC when 69a-c wag treated with TBAF. If 
BODIPY derivatives behave similarly to the dipyrromethene backbone, then dyes with 
fewer substituents, especially those with an open meso-position, are more prone to 
nucleophilic attack (e.g. the fluoride ion from TBAF).55.72 The desilylation of 
intermediate 76 for the synthesis of an anthracene-BODIPY analogue, which also lacks a 
substituent at the meso position, wag reported to occur with great difficulty (Scheme 19). 
This step wa') specifically stated as being the most troublesome in the entire synthesis and 
could only be successfully transformed if run with extreme care.11I 
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TBAF, 
~==-TMS THF,-78°C, 
51% 
Scheme 19. Desilylation of BODIPY acetylene derivativelll 
Other ways to desilylate phenols include acids such as hydrochloric acid or bases 
such as sodium hydroxide, l,l,3,3-tetramethylguanidine, and DBU (e.g. DBU is reported 
to chemoselectively desilylate aryl silyl ethers and may be used catalytically).1l2-114 
Numerous reports have shown the successful hydrolysis of silyl ethers using acids that 
I h· h . ld' 112115-117 are a so Ig Yle mg. ' The final deprotection step in the preparation of 
BODIPY-sphingosine 60 used hydrochloric acid in dioxane to deprotect the N-Boc 
group. Although the protecting group was not a silyl ether, this reaction showed that the 
BODIPY moiety was stable under these conditions with only slight decomposition 
reported.43 Thus the previous method of desilylation with TBAF was replaced with 
hydrochloric acid in tetrahydrofuran, which allowed the successful preparation of BDP-a-
Toes 42a-c with yields of 66-77% (Scheme 16). These molecules are excited at 507 nm 
and fluoresce at 511 nm with an average extinction coefficient (I':) of 83 000 M-1cm-1 in 
ethanol (Figure 24; see experimental section for individual I': values of 42a-c). 
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Figure 24. Excitation and emission spectrum of C7-BDP-a-Toc 
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2.3 Olefin isomerization and the generation of homologues 
Before the binding assays can commence, the purity of these substrates had to be 
determined using HPLC. The NMR spectra of these substrates showed what appear to be 
pure samples with all of the peaks characterizable. However, the HPLC chromatograms 
showed multiple peaks, as exemplified for C7-BDP-a-Toc in Figure 25. Liquid 
chromatography-mass spectrometry (LCMS), with electrospray ionization (ESI) a<; the 
method for detection, showed that the main peak (Rt = 13.38 min) had a masslcharge 
ratio (mlz) value that corresponded to the molecular ion of the expected molecule. All of 
the peaks with shorter retention times (Rt) gave a molecular ion that decreased in mlz by 
14 suggesting the loss of a methylene group (Figure 25). Contrarily, the peak with a 
longer retention time gave a molecular ion that increased in mlz by 14, suggesting the 
addition of a methylene group. 
These findings revealed that the samples contained homologues of varying chain 
length. The NMR spectra appeared pure because the homologues do not have chemical 
.... 80% ACN In water for 10 min 
... Flow Rate: 1 mllmln R, = 13.38 min (C7-BDP-a-Toc) 
Figure 25. HPLC Chromatogram of C7-BDP-a-Toc 42b with its homologues 
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shifts that are easily distinguishable. These homologues also coalesced into one spot on 
TLC and were eluted together during silica gel chromatography. It was initially 
suspected that the co-alkenoic acids were impure, despite the supplier's claims of high 
purity, but the HPLC of these materials showed a single peak. In fact, all of the 
intermediates that led to the synthesis of the BDP-a-Toes were pure according to HPLC 
until intermediates 68a-c obtained by metathesis. The same pattern of impurities was 
shown in these chromatograms as 42a-c (Figure 25). 
A search of the literature showed that second generation olefin metathesis 
catalysts have developed a reputation for facilitating olefin isomerization by 1,3-hydride 
shifts during the intended metathesis. 118 As a result, homologues are generated. 
Unfortunately, these side-reactions are not always reported in the many papers that 
perform metatheses. 118 It is unclear if the isomerization is caused by the ruthenium 
catalyst itself, by some decomposition product of the catalyst, or by some impurity in the 
catalyst. 118 The suggested mechanism for this isomerization is shown in Figure 26A. 119 
Another paper reports that a Grubbs catalyst decomposition product 78 possesses olefin 
isomerization activity (Figure 26B),120 but a definitive explanation for the mechanism of 
isomerization remains in dispute. 
B. 
~N~N-9-
Mes: R ., ICI NyRU~ u\~ ( • CI 
\..-NMes H CI 
78 
Figure 26. Suggested mechanism for olefin isomerization 119 and the decomposition 
product of Grubbs II catalyst that may be responsible for this event 120 
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To obtain homologues that are one or two methylenes less, the isomerization of the 
terminal alkene must occur more than once. This mechanism however does not explain 
how a homologue with an extra carbon, C8-BDP-(l-Toc reported in Figure 25, is 
produced. This homologue is produced by a different event (Figure 27) in which the 
alkene can isomerize after the first successful metathesis reaction and undergo a second 
metathesis. 118 The bisBODIPY by-products formed from these reactions are also capable 
of undergoing metathesis when reacted with vinyl Trolox 61, indicating coexisting 
metatheses with both terminal alkenes from the reactants and internal alkenes from the 
products. 
Homologues of any compound are often difficult to remove using simple 
purification methods. 121 Regular silica gel chromatography does not have the resolution 
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Figure 27. Suggested mechanism for homologues with additional carbons I 18 
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to separate these homologues. Preparative HPLC (pHPLC) can resolve these samples 
and allow milligrams of crude sample to be loaded onto an HPLC column with each 
injection (Figure 28). All of the crude samples were purified by this method to obtain 
the pure substrates. The drawback to this method is that very small amounts of crude 
sample can be loaded at a time. After 10-12 hours of continuous loadings and runs, an 
average mass of only five milligrams of pure substrate was isolated. 
pre-pHPLC 
80% ACN In water for 10 min 
Flow Rate: 1 mllmln 
post-pHPLC 
i ". 
: . ~ ! .. 
Figure 28. Purification of C7-BDP-a-Toc from its homologues by pHPLC 
A much more efficient and effective way for solving the problem with olefin 
isomerization is to consider using an alternative catalyst, one that does not exhibit this 
side-reaction. A summary of metathesis reactions performed using different catalysts is 
provided in Table 3. 
Bisphosphine ruthenium catalysts (e.g. Grubbs Generation I 79) and Schrock's 
molybdenum catalyst reportedly do not possess this isomerization activity.118 A study on 
the comparison of the potential to isomerize with Grubbs Generation I and II catalysts 
was performed by Fokou et al. 122 Grubbs Generation I showed very little isomerization 
activity that was unaffected by temperature changes or purging the system with nitrogen 
gas. Grubbs Generation II catalyst however showed isomerization even at temperatures 
48 
61 + 58b 
10 mol % 59, 79, 80, or 81, 
DCM, 50°C, 6-9 h 
# 
68b 
Table 3. Summary of metathesis reactions with various ruthenium catalysts 
Catalyst 
Conversion 
Composition 
Grubbs I 
PCY3 I." ,\CI 
~Ru='-, 
CI .... I '\, 
PCY3 Ph 
79 
0% 
from bottle 
53% 
4% C8ene 
69% C7ene 
21 % C6ene 
6% C5ene 
Grubbs II 
/\ 
N N Mes- V ---Mes 
I ",\CI Ru'~ 
CI~ I '\, 
PCY3 Ph 
59 
TFA 
47% 
95% C7ene 
5% C6ene 
chromatographed 
55% 
93% C7ene 
7% C6ene 
~ 
, I I F--l-) __ I 
Hoveyda-Grubbs II Hoveyda-Grubbs II 
(o-tolyl derivative) 
/\ 
_N N ___ 
Mes V Mes 
I.,,\CI CI~!D',f' ~ 
Ipr/ 
80 ~ 
89% 
96% C7ene 
4% C6ene 
/\ 
N N-.... I otol- V oto 
I .,,\CI 
CI~!,=O" f' ~ 
./ 
'Pr ::::::,...... 
81 
50% 
100% C7ene 
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below 60°C. An increase in temperature or purging with nitrogen gas increased the 
isomerization, as monitored by HPLC. 122 
Grubbs Generation I Catalyst was used in attempts to metathesize vinyl Trolox 61 
with heptenylBODIPY 58b, but was not active enough to complex to the bulky 
chromanol. Instead, the corresponding bisBODIPY was exclusively produced. The 
HPLC chromatogram of this by-product showed only one peak, which indicates that 
bisphosphine catalysts do not partake in olefin isomerization. I 18 
In previous attempts to eliminate this isomerization,122 acids (e.g. trifluoroacetic 
acid, phenylphosphoric acid) or benzoquinones have been added during metatheses that 
presumably titrate the ruthenium-hydride species (e.g. Figure 26B). It has also been 
reported that removal of the impurities from the catalyst by silica gel chromatography 
eliminates isomerization activity.123 Both of these methods were applied to the 
metathesis of vinyl Trolox 61 and heptenylBODIPY 58b with Grubbs Generation II 
catalyst 59 and the reactions proceeded with average yields of 50% (Table 3). Even 
though the purities were drastically improved in comparison to the original Grubbs 
Generation II-catalyzed reaction, these samples would still need to undergo pHPLC for 
further purification. 
The Hoveyda-Grubbs Generation II catalyst 80 differs from the Grubbs catalysts 
by the replacement of a phosphine and benzylidene ligand with an isopropoxy-
phenyl methylene ligand that forms a 'boomerang complex' with the metal centre. 124 
When this catalyst was used during the metathesis, an improvement in the composition 
was achieved (Table 3), but pHPLC would still need to be used for final purification. 
The o-tolyl derivative of Hoveyda-Grubbs Generation II catalyst 81 was developed to 
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facilitate easier interaction between catalyst and substrate (e.g. bulky alkene) because of 
its smaller N-heterocyclic cm'bene ligand.125 Interestingly, the use of this catalyst for the 
metathesis showed only the one peak on the HPLC chromatogram corresponding to the 
desired homologue. 
The results from Table 3 seem to show that the o-tolyl derivative of Hoveyda 
Grubbs Generation II catalyst, 81, hm; the lowest activity for olefin isomerization and 
should replace Grubbs Generation II catalyst in future metatheses. With BDP-a-Tocs 
42a-c in hand, binding a'isays to a-TTP could proceed (see Section 2.5). 
2.4 Synthesis of a Thienyl Derivative of BDP-a-Toe 
It was also our intention to synthesize another fluorescent analogue of vitamin E 
that has extended conjugation of the fluorophore by incorporating a thienyl group 
(thienylBODIPY or TBDP) (Figure 29). This new fluorophore is larger than the simpler 
dimethylBODIPY and further accentuates the curvature of the analogue in 82. Molecular 
modeling of this analogue revealed that a methylene bridge of four carbons would afford 
a molecular length most similar to C9-NBD-a-Toc lId. In addition to C4-TBDP-a-Toc 
82a, a five methylene bridged analogue, 82b, was made. 
To synthesize this thienyl derivative, a pyrrole-2-carboxaldehyde that possesses a 
thienyl group instead of two methyl groups was required. Unlike 3,5-dimethylpyrrole-2-
carboxaldehyde, 5-(2'-thienyl)pyrrole-2-carboxaldehyde is not commercially available 
Figure 29. Structure of the TBDP-a-Toc target molecule 
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and must be prepared. Stille coupling using stannylpyrroles has been used to make 2-
arylpyrroles, but tin is a toxic substance. 126 The Paal-Knorr cyclization of 4-oxo-4-
phenylbutanal with ammonium acetate is reported to synthesize 2-arylpyrroles de novo.127 
This method is high yielding and can be used to prepare 2-arylpyrroles on a large scale. 
A methyl analogue of thienylpyrrole was reported to yield 55% of the corresponding 2-
aryl derivative by this reaction. 127 Other methods for the preparation of 2-arylpyrroles 
include the photochemical arylation of 5-iodo-2-formyJpyrrole with thiophene,128 the 
condensation between methylazidoacetates and f)-aryl acroleins with subsequent 
cyclization and decarboxylation,84 and many more alternative methods that require de 
novo synthesis of the pyrrole ring. 129,130 
A much simpler way of making 2-arylpyrroles is through the Suzuki coupling of 
arylboronic acids and N-Boc-2-bromopyrroles 83 (Scheme 20). This type of cross 
coupling has been used before to generate other BODIPY dyes with different 
photophysical properties.27 Successful coupling of 83 to various arylboronic acids, such 
as phenyl- and naphthylboronic acid, were reported with yields of 90% or greater.27,131 
Pyrrylboronic acids coupled to 2-arylbromides have been used as the alternative for these 
couplings,132 but not often because of their inherent instabilities (e.g. deboronification of 
pyrroJe upon heating).133 This method was chosen to generate TBDP-a-Tocs 82a-b. 
83 can be prepared by brominating pyrrole and trapping the unstable 2-
bromopyrrole intermediate in situ with a N-protecting group that withdraws electrons 
0--N Br 
Boc 
83 
R,B(OH12, Na2C03, Pd(PPh31., 
PhMelMeOH 5: 1, 80°C 
84: 99% 
85: 93% 
86: 90% 
87: 99% 
n 84(R,=Ph) 
i( >-- 85 (R, = 1-Naph) 
N R, 86 (R, = 4-MeOCsH.) 
Boc 87 (R, = 4-FCsH.) 
Scheme 20. Suzuki coupling to generate various 2-arylpyrroles27 
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from the aromatic ring, such as Boc (Scheme 21). 1,3-Dibromo-5,5-dimethylhydantoin 
is reported to be much more regioselective than N-bromosuccinimide and therefore 
became the brominating agent of choice.89,J34 N-Boc-2-bromopyrroJe 83 was prepared by 
this method with a yield of 90%. 
i. 1.1·Azobis(cyclohexanecarbonitrile), 
1.3-dibromo-S.S·-dimelhylhydanloin. 
THF. _78°C Boc Boc 
H 
N o 
Ii. (Bocl20. OMAP. TEA. ~ 2-lhienylboronic acid. Pd(OAc12. SPhos. 
_-7_8°_C_Io_rt ______ V Br K3P04. n-bulanol. 100 OC (~; n ~S/ 
90% 83 75% 
Scheme 21. Synthesis of 5-(2'-thienyl)pyrrole-2-carboxaldehyde 
88 
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When the Suzuki coupling of 83 to 2-thienylboronic acid was attempted using the 
conditions listed in Scheme 20, product 88 was not produced. Instead, the reaction 
turned dark brown and 83 was never recovered. Unfortunately the paper that reported 
this method did not use heteroarylboronic acids.27 Difficulties often arise during the 
coupling of thienylboronic acids. Their instability in polar solvents often result~ in the 
protodeboronation of the aromatic ring.83 
In recent years, a higher yielding and more efficient Suzuki-Miyaura coupling 
reaction that uses a palladium precatalyst and a monophosphine ligand (SPhos) was 
repOlted.83 This new approach is much more reactive than the method reported 
previousll7 because the catalyst generated in situ is able to bind to 2-thienylboronic 
acid. 83 When this new catalytic system wa~ used to couple the boronic acid to 83, 2-
thienylpyrrole 88 was cleanly synthesized in 75% yield (Scheme 21). 
S3 
With 88 now prepared, it must be deprotected and fonnylated to generate 89 that 
is required for the condensation. The Vilsmeier-Haack reaction with thienylpyrroles has 
been shown to selectively formylate the pyrrole ring because of its greater electron-
richness than thiophene.84 2-Thienylpyrroles are reported to be unstable species, even at 
reduced temperatures (e.g. -20 oC).62 Stabilization is only obtained after an electron-
withdrawing group (e.g. N-Boc, CHO) is added because the electron-richness is lowered. 
Bal)ed on our earlier experience with the Vilsmeier-Haack reaction on N-Boc-
succinamidal 26, the Boc protecting group was removed because of the acidic conditions. 
It was thought that if the N-Boc group of 88 is removed in addition to formylation of the 
pyrrole ring, then 89 could be made in one-pot without isolating the unstable 2-
thienylpyrrole intermediate. 5-(2'-Thienyl)pyrrole-2-carboxaldehyde 89 was successfully 
prepared by this method in 59% yield. 
Both 3-butenoic and 4-pentenoic acid underwent the same chemistry as the long-
chain ro-aJkenoic acids in order to prepare the alkenylpyrroJes needed for condensation 
(Scheme 22). The yields from reacting 3-butenoic acid were much lower than those 
obtained previously, however. These reactions on short-chain ro-alkenoic acid have not 
been reported and the results seem to indicate that 3-butenoic acid is not amenable to 
these conditions. The generation of pyridyJ thioate 90b and ketopyrrole 9tb from 4-
pentenoic acid gave yields that were much more similar to the long-chain ro-alkenoic 
acids (Scheme 22). 
2.2"pY~2. PPh3. ~ . . II ~ [pyrrylMgCIJ. 
/'MnC02H -'-P=hM.;.;;..e __ ..... ."PHn"sAN) THF. ·78 "C. 
n=1:51% n=l:66% 
n = 2: 88% n = 2: 97% 
90a-b (n = 1-2) 
o 
~ 
91a-b (n = 1-2) 
Scheme 22. Synthesis of short-chained ketopyrroles 
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The reduction of butenoylpyrrole 91a with sodium borohydride followed by 
pyrrole condensation and treatment with boron trifluoride diethyl etherate failed to give 
the corresponding alkenylTBDP. Instead, a TBDP fluorophore with a fully saturated 
butyl tail was generated in 6% yield. The saturation of the butenyl group was likely 
caused by the isomerization of butenoylpyrrole 91a to the a,~-unsaturated ketone during 
treatment with sodium borohydride followed by a 1,4-reduction (see Scheme 23). 
Failure to synthesize butenylTBDP by this method eliminated access to C4-TBDP-a-Toc 
82a. 
~ 
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Scheme 23. Synthesis of pentenylTBDP 94 from its ketopyrrole 
Reduction of ketopyrrole 91b followed by dipyrromethene formation and 
treatment with boron trifluoride diethyl etherate yielded 94 in 11 % (over two steps) 
(Scheme 23). Unlike the red oils produced by the dimethylBODIPY intermediates, this 
thienyl derivative was a dark purple oil. This intermediate is excited at 561 nm and 
fluoresces at 570 nm with an extinction coefficient (£) of 78 000 M-1cm-1 (Figure 30). 
The overall yield was considerably lower than that obtained from the dimethylBODIPY 
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Figure 30. Excitation and emission spectrum of pentenylTBDP 
series (i.e. 34-40%), likely because the fewer substituents on this dipyrromethene 
backbone lower the stability. 
Olefin metathesis between vinyl Trolox 61 and 94 using the o-tolyl derivative of 
Hoveyda-Grubbs Generation II catalyst 81 generated product 95 with 14% yield (Scheme 
24). This yield was much lower than those obtained from the previous metatheses. This 
is because the alkene on 94 is not only closer to the fluorophore, which increases steric 
hindrance, but also this fluorophore is much bulkier than the dimethylBODIPY 
fluorophore. Due to the low yields obtained from the last two reactions, only milligrams 
of 95 were obtained. This was not enough material to proceed through the hydrogenation 
so further attempts to produce 82b were halted (Scheme 24). 
61 94 
HO 
82b 
TBSO 
Hoveyda-Grubbs Gil Cat. (o-tolyl) 81, 
OCM,40"C 
14% 
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95 
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Scheme 24. Metathesis and unperformed chemistry (dashed arrows) ofC5-TBDP-a.-Toc 
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2.5 Fluorescence Binding Studies ofBDP-a-Toc 
In order for BDP-a-Tocs 42a-e to be of any utility they must possess some 
binding ability towards a-TIP. This binding should be both specific and reversible in 
order for these fluorescent probes to be suitable analogues of vitamin E. Previously, the 
dissociation constants (Kd) of fluorescent vitamin E analogues 11a-d, 12a-d, 13a-d, and 
14a-d were determined (Table 4) and C9-NBD-a-Toe lId wa~ shown to have the highest 
affinity to the protein.79 The dissociation constant for a-tocopherol, the natural ligand for 
a-TTP, is 25 nM.ll The Kd values for DAN-a-Tocs 13a-d and NMA-a-Toes 14a-d could 
not be detennined due to non-saturable binding with a-TIP. Only C9-AO-a-Toc 12d 
from the anthroyloxy series was found to bind specifically.79 
Table 4 D' . IssoclatIon cons ants or f; fl h uorescent tocoPJ ero an al ogues a- an 11 d d 12d79 
NBD-a-Toc Kd (nM) AO-a-Toc Kd (nM) 
lIa 299 ± 37 12a -
lIb 106 ±21 12b -
11e 142 ± 35 12e -
lId 56± 15 12d 279 ± 124 
The dissociation constants defined as [a-TIP][ligand]/{a-TIP-ligand] were 
assessed from fluorescence titrations of TIP with BDP-a-Tocs 42a-c and calculated from 
the one-site binding model using Prism software. The average results of the multiple 
titrations on a range of ligand concentrations (3-640 nM) are listed in Table 5. C8-BDP-
a-Toc 42e appears to have the best affinity (Kd = 100 nM) for a-TIP. Literatureshows 
that the biological function of some analogues generally increases as the linker between 
the pharmacophore and fluorophore is increalO)ed.62,135 Although the results from these 
binding assays follow this trend, alO) seen with the Kd values of both NBD-a-Tocs and 
BDP-a-Tocs, it is just a general rule and does not apply to every calO)e. 
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Table 5. Dissociation constants for BDP-a-Tocs 42a-c 
BDP-a-Toc Kd (nM) 
42a 436 ± 28 
42b 146 ± 11 
42c 98±6 
These binding assays were run with the concentration of a-TIP set to 1 ~. As 
the concentration of each ligand was increased upon subsequent additions, the titration 
curves were gradually produced (Figures 31-33) and were then used to detennine the 
dissociation constants. Oddly, the maximal fluorescence appears to plateau at 
concentrations of ligand (- 650 nM) that is sub-stoichiometric to the protein (I ~M). 
These results were not observed previously with the other fluorescent vitamin E 
analogues. C9-NBD-a-Toe wa", needed at concentrations five times in excess to protein 
until a plateau was reached from its binding curve.79 This was expected since binding is 
in equilibrium. Radioligand binding experiments have previously established that one 
molecule of a-tocopherol bound per molecule of a-TIP, 136 so obtaining sub-
stoichiometric plateaus (Figure 31-33) cannot be from non-native protein. 
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Figure 31. Titration curves showing the increase in fluorescence intensity at 514 nm 
during sequential additions of the C6-BDP-a-Toc, 42a (black squares), to a 1.0 ~ 
solution of a-TIP in SET buffer. The curves are fitted to a one-site binding model. 
A verages and standard errors of triplicate data sets are reported. !...ex = 506 nm. 
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Figure 32. Titration curves showing the increase in fluorescence intensity at 514 nm 
during sequential additions of the C7-BDP-a-Toc, 42b (black squares), to a 1,.0 J.1M 
solution of a-TIP in SET buffer. The curves are fitted to a one-site binding model. 
Averages and standard errors of triplicate data sets are reported. !-ex = 506 nm. 
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Figure 33. Titration curves showing the increase in fluorescence intensity at 514 nm 
during sequential additions of the C8-BDP-a-Toc, 42c (black squares), t-o a 1.0 J1M 
solution of a-TIP in SET buffer. Additional binding curves of 42c to 1.0 J1M lysozyme 
and 1.0 J1M BSA are also reported. The curves are fitted to a one-site binding model. 
A verages and standard errors of triplicate data sets are reported. !-ex = 5D6 nm. 
The fluorescence signal plateaus at sub-stoichiometric concentrations of ligand-
to-protein initially raised concerns with non-specific binding of the ligand to a-TIP, but 
that does not explain why the Kd values are low. Additional binding curves for both 
lysozyme and bovine serum albumin (BSA) with C8-BDP-a-Toc were run. Lysozyme is 
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a protein with no hydrophobic pockets that would allow binding to the ligand and 
therefore acted as a negative control. BSA possesses many hydrophobic pockets that 
does allow non-specific binding with the ligand, 137,138 a~ is seen in Figure 33. 
Despite the ability of 42c to bind non-specifically to BSA, it was important to 
demonstrate that we could compete the ligand from a-TIP to ensure that a specific 
binding event was observed. To achieve this, the protein was first equilibrated with 42c 
and then titrated with a-tocopherol. This assay wa~ then repeated using a solution of 
cholesterol in absolute ethanol as a non-competent control since cholesterol is known to 
have very low affinity to a-TTP.ll 
C8-BDP-a-Toc (Figure 34) exhibits a dose-dependent decrease in fluorescence 
upon the addition of a-tocopherol suggesting that the environmentally sensitive 
fluorophore is displaced from the hydrophobic-binding pocket of a-TIP by the native 
ligand. By 4 ~ of a-tocopherol, there appears to be near total displacement of C8-BDP-
a-Toc by the native ligand. There is an obvious difference in the fraction of remaining 
1 .. 5 
.11 
• 
• 
11 Cholesterol 
.a~ Tocopherol 
• O.O+---r-----,r---....,.--..... ----, 
o 1 2 3 .. 5 
[Competitor) jiM 
Figure 34. Competitive displacement of 1 ~ C8-BDP-a-Toc, 42c, bound to 0.2 ~ a-
TIP in SET buffer by addition of increasing amounts of (RRR)-a-tocopherol or 
cholesterol in ethanol. Fluorescence was monitored at 514 nm. Averages and standard 
errors of triplicate data sets are reported for tocopherol. 
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fluorescence when cholesterol is added to this assay as the control. These results indicate 
that there is indeed a specific binding event that occurs between C8-BDP-a-Toc and a-
TTP. 
It was observed that upon adding increasing amounts of cholesterol, the fluorescence 
began to decrease in intensity (Figure 35). At 40 J,tM cholesterol, the fraction of 
remaining fluorescence was reduced to near 50%. Since cholesterol does not interact 
with a-TTP, it was speculated that ethanol, the solvent in which all stock ligand and 
control solutions were made, wali in fact affecting the affinity between C8-BDP-a-Toc 
and a-TIP. It was previously shown that ethanol affects the binding of sterol carrier 
protein-2 (SCP-2) with several lipids, such as cholesterol, PC, and stearic acid. 139 In the 
presence of 25 mM ethanol, NBD-cholesterol and NBP-PC were shown to have reduced 
affinity with the carrier protein. In the absence of ethanol, NBD-cholesterol and NBD-
PC have association constants of 8.95 ± 0.6 X 107 M and 9.1 ± 1 X 106 M to SCP-2, 
respectively. By 25 mM of ethanol, when significant differences in binding for both 
ligands were first observed, the association constants were reduced to approximately 70% 
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Figure 35. The effect of binding of C8-BDP-a-Toc to a-TTP in SET buffer by addition 
of ethanol. Fluorescence was monitored at 514 nm. A verages and standard errors of 
triplicate data sets are reported for ethanol. 
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of the original values. 139 The decrease in fluorescence of C8-BDP-a-Toc bound to a-TIP 
first becomes apparent at 3 ~ cholesterol in Figure 34, which equates to 6 fll (or 34 
mM) ethanol (total cuvette volume: 3 ml). 
It was suggested that ethanol interacts with the hydrophobic sites within the 
binding pocket of SCP-2 and inhibits the interaction with the ligand. 139 Therefore, 
absolute ethanol was used to titrate a sample of protein equilibrated with 42c and was 
shown to have a curve identical to the cholesterol control, confirming that ethanol was in 
fact reducing affinity of ligand to a-TTP (Figure 35). This would also explain how a 
sub-stoichiometric plateau from the binding curves (Figures 31-33) seems to be obtained. 
Ethanol removes the BDP-a-Tocs from a-TIP, appearing to 'saturate' at ligand 
concentrations less than the protein. This is the point at which ligand removal by ethanol 
was competing etfectively with the binding of ligand to a-TIP. When the additions of 
ligand in ethanol were continued beyond the point of plateau, a decrease in fluorescence 
intensity was observed, suggesting that the removal of ligand from a-TIP by ethanol was 
occurring at a larger rate than the rate of ligand binding. There was a slight increase in 
fluorescence after the addition of 30-40 ~ of (RRR)-a-tocopherol as the competitor 
(Figure 35), but this is likely because unbound C8-BDP-a-Toc is exposed to increa"ing 
concentrations of ethanol, in which the ligand fluoresces more intensely. Alternative 
organic solvents were sought that did not remove the nature of the binding site of a-TTP 
(e.g. DMF, THF) but each showed a decrease in fluorescence greater than ethanol. 
Despite these solvents seeming to affect the nature of the binding site, it is certain that 
C8-BDP-u-Toc 42c binds to cr-TIP specifically with a fairly low Kd. For now, the 
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binding constants obtained with ethanol as the best organic solvent (Table 5) can be 
considered as approximations. 
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3 CONCLUSIONS AND FUTURE PERSPECTIVES 
With the successful preparation and characterization of the BDP-a-Tocs series 
now completed, these molecules can be used to further study the intracellular transfer of 
vitamin E. The synthesis of these molecules was met with challenges unprecedented to 
the syntheses of our previous analogues but all were eventually overcome. C8-BDP-a-
Toc 42c has been shown to bind specifically and reversibly to a-TIP, being displaced by 
natural ligand (RRR)-a-tocopherol. This ligand also has great affinity towards the protein 
with an apparent dissociation constant of 98 ± 6 nM. 
The next step for this project is to incorporate these ligands into cells in vitro to 
learn about the transfer of tocopherols in hepatocytes. In addition, the synthesis of C5-
TBDP-a-Toc shall continue so that it can one day be used alongside C8-BDP-a-Toc to 
study the storage mechanism of excess vitamin E in cells. 
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4 EXPERIMENTAL 
4.1 General Methods 
4.1.1 Chromatography 
Flash chromatography was carried out on either silica gel (70-230 A. mesh, Alfa 
Aesar, Ward Hill, MA or Desican, Inc., Markham, ON) or alumina gel (150 A. mesh, 
Sigma-Aldrich, Oakville, ON) with the indicated solvent systems. Analytical thin layer 
chromatography (TLC) was performed on either silica gel 60 A. F254 plates (EMD 
Chemicals, Inc.) or alumina gel 60 A. F254 plates (EM Science). 
4.1.2 Spectroscopy 
Spectroscopic analysis of compounds was performed by IH, 13C, lIB, and I9F 
NMR obtained using a Bruker Avance DPX-3oo Digital FT-NMR spectrometer at 300 
(or 600) MHz, 75 (or 151) MHz, 96 (or 193) MHz, and 282 MHz, respectively. 
Cambridge Isotope Laboratories, Inc. deuterated chloroform (99.8% pure) was used as 
the solvent with the internal reference of residual chloroform eH = 7.26 ppm, I3C = 77.0 
ppm). Chemical shifts are reported in ppm (6) (multiplicity, coupling constant in Hz, 
number of protons, and assignment). Multiplicity is designated using the following 
abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). IH NMR (300 
MHz) possesses an error of ± 0.45 Hz. Low resolution mass spectra (MS) were recorded 
on a Carlo Erbal Kratos GCI MS Concept 1 S double focusing mass spectrometer 
interfaced to a Kratos DART acquisition system and a SUN SPARC workstation. 
Samples were introduced through a direct inlet system and ions were generated using 
electron impact (EI) at 70 eV, ESI, or fast atom bombardment (FAB) sources and are 
reported as mlz values for the parent peak and major fragments. UV/Vis spectra were 
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obtained using Unicam UVNis Spectrometer in conjunction with Vision32 software. 
Fluorimetric data was obtained using QuantaMa~ter Model QM-2001-4 cuvette-ba~ed L-
format scanning spectrofluorometer from Photon Technology International (PTI) in 
conjunction with FeliX32 program software. All cuvettes used were made of special 
optical glass (10.00 mm, 3 ml) and provided by Hellma. HPLC was performed using a 
Synergi Hydro-RP column (C18, 4 J,.Lm, 150x4.60 mm) by Phenomenex on a Waters 626 
pump and photodiode array detector in combination with Millennium 32 v.3.2 program 
software. pHPLC was performed using a PrimeSphere column (CI8, 5 Jlffi, 2S0xlO.00 
mm) by Phenomenex on a Hitachi L-60oo pump in combination with a Hitachi Integrator 
D-7500 for output. 
4.2 Preparation of Compounds 
Soc 
I 
~o 
4.2.1 Synthesis of telt-butyl 2,5-dioxopyrrolidine-1-carboxylate (25)90 
To a solution of succinimide (5.00 g, 50.5 mmoI) in acetonitrile (100 ml) was 
added BOC20 (13.9 ml, 60.6 mmoI) and DMAP (617 mg, 5.05 mmol). After 4 h, the 
solvent was removed in vacuo and the crude material was subjected to flash 
chromatography (hexaneslethyl acetate 5:2). The eluted material was then recrystallized 
from hexanes/dichloromethane to afford 25 (7.76 g, 39.0 mmol, 77%). 
Pale yellow, square crystals, Rf = (0.20,hexaneslethyI acetate 5:2, visualized by 
KMn04), mp 89-90 °C [lit.90 86°C] . IH NMR (300 MHz, CDCb) 02.74 (s, 4H, 2xCfu), 
1.54 (s, 9H, 3xCH3). l3C NMR (75 MHz, CDCh) 0 172.8, 146.4,86.1, 28.4, 27.6. MS 
(+EI) m/z 184 ([M-CH3t, 1.4%),144 (2.0%), 126 (44.8%), 100 (31.5%), 70 (Hi.8%), 57 
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(100%), 41 (64.0%). HRMS (EI) calculated for CgHION04°+: 184.06098, found 
184.06064. 
4.2.2 Synthesis of ten-butyI2-hydroxy-5-oxopyrrolidine-l-carboxylate (26)90 
25 (513 mg, 2.58 mmol) was dissolved in a tetrahydrofuranJethanol mixture 1:1 
(7.5 ml) and cooled to -50°C. Sodium borohydride (209 mg, 5.40 mmol) was added 
slowly over 0.5 h so that the temperature did not to exceed -50°C. After 5 h, 5% 
hydrochloric acid (1.3 ml) was added to quench the reaction a.1l the temperature was 
slowly raised to ambient. The mixture was then filtered using a Hirsch funnel and the 
filtrate was condensed in vacuo. The residue was extracted with dichloromethane and 
then chromatographed on silica (ethyl acetate/hexanes 8: 1). Recrystallization from 
hexanes afforded pure amidal 26 (340 mg, 1.69 mmol, 66%). 
White solid, Rf = (0.45, ethyl acetate/hexanes 4:1, visualized by KMn04), mp 77-
78°C [lit.90 78-79 0C]. IH NMR (300 MHz, CDCh) 35.57-5.55 (m, IH, CHOH), 4.36-
4.36 (d, J = 2.1 Hz, IH, OID, 2.64-2.52 (m, IH, CfuC=O), 2.27-2.17 (m, IH, CfuC=O), 
2.09-1.96 (m, IH, CfuCHOH), 1.85-1.75 (m, IH, CH,CHOH), 1.35 (s, 9H, 3xCfu). BC 
NMR (75 MHz, CDCh) 3 173.1, 149.8, 83.1,81.6,30.1,27.5,25.4. MS (+EI) mlz 201 
(M+, 0.8%),186 (1.1%),146 (15.0%),128 (11.9%), 85 (30.1%), 57 (100%), 41 (52.0%). 
HRMS (EI) calculated for C9H1SN04: 201.10011, found 201.09653. 
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4.2.3 Synthesis of ten-butyl hypochlorite (28)92 
Javex® bleach (0.5 1, 5.25% NaOCI) was cooled to 0 °C in the absence of light. 
Next, a solution of telt-butanol (37.0 ml, 390 mmol) and glacial acetic acid (24.5 ml, 428 
mol) was added and stirred for 3 min. From this reaction mixture, the aqueous layer was 
removed and the organic layer was washed with 10% aqueous sodium carbonate (50 ml) 
and then water (50 ml). Product 28 (21.7 g, 0.200 mol, 51 %) was a yellow transparent 
liquid which must be stored below 0 °C in an amber jar. 
~~~CHO , 1/ ~ Ii 
CI 
H 
CI---(Ny _CHo )-J 
CI 
4.2.4 Synthesis of 5-chloro-lH-pyrrole-2-carbaldehyde (23), 4-chloro-lH-pyrrole-2-
carbaldehyde (29), and 4,5-dichloro-lH-pyrrole-2-carbaldehyde (30)91 
Pyrrole-2-carboxaldehyde (4.75 g, 50.0 mmol) was dissolved in carbon 
tetrachloride (200 ml) and cooled to 0 °C. Then a solution of tert-butyl hypochlorite 
(5.42 g, 50.0 mmol) in carbon tetrachloride (100 ml) was added dropwise using an 
addition funnel. After 3 h, the solvent wa<; removed under reduced pressure and the crude 
material was chromatographed (hexanesltetrahydrofuran 15:1) to 23 (1.68 g, 13.0 mmol, 
26%) and a crude mixture of 29 and 30. 29 (667 mg, 5.15 mmol, 10%) can be isolated 
from 30 (888 mg, 5.41 mmol, 11 %) from recrystallization in hexanes/diethyl ether 1: 1 
23: off-white flaky powder, Rf = (0.15, hexanes/tetrahydrofuran 15:1), mp 103-
105°C [lit.90 110°C]. lH NMR (300 MHz, CDCh) 0 11.06 (br s, IH, NH), 9.38 (s, IH, 
CHO), 6.97-6.94 (m, tH, CHCCHO), 6.23-6.21 (m, IH, CHCCI). l3C NMR (75 MHz, 
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CDCb) 8 178.5, 131.7, 126.6, 110.1. MS (+EI) mlz 129 (M+, 100%), 100 (34.2%), 73 
(35.9%), 64 (15.6%), 50 (13.4%), 41 (12.5%). HRMS (El) calculated for Cs~CINO: 
128.99814, found 128.99770. 
29: light brown lustrous needles, ~f = (0.25, hexanes/tetrahydrofuran 15:1), mp 
128-129 °C [lit. l40 129-129.5 0C]. 'H NMR (300 MHz, CDCh) 8 10.35 (br s, IH, NH), 
9.44 (s, IH, CHO), 7.11-7.10 (m, IH, CHNH), 6.91-6.90 (m, IH, CHCCHO). '3C NMR 
(75 MHz, CDCb) 8 179.2, 131.6, 124.2, 119.9, 115.1. MS (+EI) mlz 129 (M\ 100%), 
100 (38.3%), 73 (27.9%), 65 (17.0%), 44 (14.7%). HRMS (EI) calculated for CsH4CINO: 
128.99814, found 128.99829. 
30: off-white needles, ~ = {0.25, hexanes/tetrahydrofuran 15:1), mp 149°C 
[lit.'40 143.5-145 0C]. 'H NMR (300 MHz, CDCh) 8 10.46 (br s, IH, NH), 9.55 (s, IH, 
CHO),6.21-6.20(d,J=2.1 Hz, IH,CHNH). 13CNMR(75MHz,CDCh)8176.4, 127.3, 
125.4, 125.2, 110.2. MS (+EI) mlz 162 ([M-Ht, 100%), 134 (20.1 %), 107 (21.9%), 73 
(25.5%), 55 (16.5%), 45 (18.6%). HRMS (EI) calculated for CSH3C}zNO: 162.95917, 
found 162.95920. 
.~ 
CI---<,~~ HBr 
U 
4.2.5 Synthesis of (Z)-2-chloro-5-«(3,5-dimethyl-2H -pyrrol-2-ylidene )methyl)-lH-
pyrrole hydrobromide (34i6 
23 (102 mg, 0.790 mmol) and 2,4-dimethylpyrrole (81.3 J.d, 0.790 mmol) were 
dissolved in absolute ethanol (3.5 ml) and cooled to 0 dc. Hydrobromic acid (133 JlI, 
1.22 mmol) wa~ added dropwise and this was stirred for 1 h. The mixture wa~ filtered 
.<J9 
using a Hirsch funnel and the precipitate was washed with cold ethanol to yield 34 (104.5 
mg, 0.360 mmol, 46%). 
Bright orange powder, R,. = (0.93, dichloromethane/methanol 10:1). IH NMR 
(300 MHz, CDCI3) () 13.91 (hr m, 2H, 2xNH), 7.09-7.07 (m, 2H), 6.40-6.38 (m, 1H), 
6.30 (s, IH), 2.75 (s, 3H, Cfu), 2.38 (s, 3H, CH3).13C NMR (75 MHz, CDCh) 8 162.2, 
150.2, 138.4, 133.2, 129.4, 126.4, 124.4, 120.1, 114.7, 15.0, 12.3. MS (+FAB) mJz 207 
([MHt, 100%), 171 (6.7%). HRMS (FAB) calculated for Cll H12N2Cl+: 207.06890, 
found 207.06722. 
HBr 
CI 
4.2.6 Syntbesis of (Z)-2,3-dicbloro-S-( (3,S-dimetbyl-2H -pyrrol-2-ylidene )metbyl)-lH-
pyrrole bydrobromide (35)26 
30 (100 mg, 0.610 mmol) and 2,4-dimethylpyrrole ({j2.8 Ill, 0.610 mmo1) were 
dissolved in absolute ethanol (3.5 ml) and cooled to 0 0c. Hydrobromic acid (103 Ill, 
0.946 mmol) was added dropwise and this wa~ stirred for 1 h. The mixture was filtered 
using a Hirsch funnel and the precipitate wa~ washed with cold ethanol to yield 35 (95.5 
mg, 0.299 mmol, 49%). 
Bright reddish-orange powder, Rf = (0.85, dichloromethane/methanol 20: 1). IH 
NMR (300 MHz, CDCh) () 14.00-13.94 (br m, 2H, 2xNID, 7.26 (d, J = 2.1 Hz, IH), 
6.40-6.39 (d, J = 2.1 Hz, IH), 6.34 (s, IH), 2.75 (s, 3H, Cfu), 2.41 (s, 3H, CH3). l3C 
NMR (75 MHz, CDCh) () 163.8, 15l.1, 136.5, 134.1, 129.9, 123.1, 120.7, 119.7, 113.4, 
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15.2, 12.3. MS (+FAB) m/z 241 ([MHt, 100%), 170 (8.2%), 57 (7.3%). HRMS (FAB) 
calculated for CllHIlN2Ch+: 241.02993, found 241.02948. 
Cl 
4.2.7 Synthesis of 7 -ch]oro-S,S-difluoro-l,3-dimethy]-SH-dipyrro]o[1,2-c: l' ,2'-
f][1,3,2]diazaborinin-4-ium-S-uide (38i6 
To a solution of 34 (105 mg, 0.363 mmol) in toluene (15 ml) was added boron 
trifluoride diethyl etherate (230 J.d, 1.82 mmol) and DBU (163 ,.d, 1.09 mmol). The 
resulting mixture wac; heated to 90 cC for 2 h. Afterward, the solution was wac;hed with 
water and the crude material wac; purified via chromatography (hexanes/diethyl ether 3:2) 
to give desired fluorophore 38 "(66.8 mg, 0.261 mmol, 72%). 
Red lustrous needles, Rf= (0.30, hexanes/diethyl ether 3:2), mp 166-167 cC. Amax 
excitation in ethanol = 500 nm (Esoo = 58 000 M-1cm-1), Amax emission in ethanol = 508 
nm. lH NMR (300 MHz, CDCh) 0 7.03 (s, IH), 6.83-6.82 (d, J = 2.4 Hz, IH), 6.26-6.25 
(d, J = 2.1 Hz, 1H), 6.15 (s, IH), 2.58 (s, 3H, CH3), 2.23 (s, 3H, CH3). 13C NMR OS 
MHz, CDCh) 0 163.5, 145.8, 138.4, 136.3, 131.9, 126.7, 123.3, 121.6, 115.8. MS (+EI) 
mlz 254 (M+, 100%),234 ([M-HF]+' 28.7%), 218 (27.4%), 204 (14.6%), 117 (20.9%), 65 
(5.9%), 49 (5.8%). HRMS (EI) calculated for ClIHlOBCIN2F2: 254.05936, found 
254.05868. 
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4.2.8 Synthesis of 7 ,8-dichloro-5,5-difluoro-l,3-dimethyl-5H-dipyrrolo[1,2-c:l' ,2'-
f][1,3,2]diazaborinin-4-ium-5-uide (39i6 
To a solution of 35 (90.0 mg, 0.290 mmol) in toluene (15 ml) was added boron 
trifluoride diethyl etherate (348 Ill, 2.74 mmol) and DBU (246 J..t!, 1.65 mmol). The 
resulting mixture wa') heated to 90°C for 2 h. Afterward, the solution was wa'ihed with 
water and the crude material was purified via silica gel -chromatography (hexanes/diethyl 
ether 3:2) to give desired fluorophore 39 (43.0 mg, 0.151 mmol,52%). 
Red lustrous needles, Rf = (0.35, hexanes/diethyl ether 3:2), decomposed when 
heated to 150°C. Amax excitation in ethanol = 497 nm (E497 = 51 000 M·1cm- I ), Amax 
emission in ethanol = 506 nm. IH NMR (300 MHz, CDCh) ~ 7.16 (s, IH), 6.28 (s, IH), 
6.22 (s, IH), 2.60 (s, 3H, CH3), 2.30 (s, 3H, CH3). l3C NMR (75 MHz, CDCh) ~ 165.3, 
146.6, 136.9, 136.8, 129.0, 128.2, 122.5, 119.5, 114.3, 15.4, 11.5. MS (+EI) mlz 288 (M+, 
100%), 268 ([M-HFt, 35.6%), 253 (25.4%), 218 (57.8%), 169 (11.7%), 134 (25.7%), 
109 (18.7%), 69 (10.7%), 57 (10.0%), 43 (8.9%). HRMS (EI) calculated for 
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4.2.9 Synthesis of 5-bromo-1H-pyrrole-2-carbaldehyde (31), 4-bromo-1H-pyrrole-2-
carbaldehyde (32), and 4,5-dibromo-lH -pyrrole-2-carbaldehyde (33)93 
Pyrrole-2-carboxaldehyde (2.55 g, 26.8 mmol) was dissolved in carbon 
tetrachloride (200 ml) and heated to 70°C. To this wa~ added dropwise a solution of 
bromine (1.38 ml, 26.8 mmol) in carbon tetrachloride (50 ml). After 1.5 h, 20% aqueous 
sodium carbonate was added to neutralize evolved HBr and the reaction mixture was 
extracted with diethyl ether. Chromatography (hexanes/tetrahydrofuran 15:1) afforded 
two partially purified fractions. The first fraction <:ontained 32 (889.3 mg, 5.11 mmol, 
19%) and recovered pyrrole-2-carboxaldehyde (443.7 mg, 4.67 mmol). From this 
mixture, 32 can be further purified by recrystallization from hexanes/diethyl ether 1: 1. 
The second fraction contained 31 (676.6 mg, 3.89 mmol, 14%) and 33 (983.4 mg, 3.89 
mmol, 14%). From this mixture, 31 can be further puritied by sublimation (60 °C at 0.5 
Torr for 6 h). 
31: white lustrous crystals, ~f = (0.20, hexanes/tetrahydrofuran 15:1), mp 90-92 
°C [lit.93 93-94 0C]. lH NMR (300 MHz, CDCI3) 3 10.99 (br s, 1H, NH), 9.37 (s, 1H, 
CHO),6.94-6.91 (dd, J = 4.2 Hz, J' = 2.4 Hz, lH, CHCCHO), 6.23-6.21 (dd, J = 4.2 Hz, 
J' = 2.4 Hz, lH, CHCBr). l3C NMR (75 MHz, CDCh) 8 178.2, 133.7, 123.2, 113.8, 
112.0. MS (+EI) mlz 173 (M+, 100%), 144 (17.3%), 119 (12.2%), 93 (3.3%), 79 (2.2%), 
64 (8.0%), 44 (7.2%). HRMS (EI) calculated for CsH,J3rNO: 172.94762, found 
172.94685. 
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32: white lustrous crystals, Rf= (0.10, hexanes/tetrahydrofuran 15:1), mp 118-121 
°C [lit.93 123-124 0c] . IH NMR (300 MHz, CDCI)) (5 10.15 (br s, IH, NID, 9.46 (s, lH, 
CHO), 7.14-7.13 (dd, J = 1.5 Hz, J' = 1.5 Hz, IH, CHNH), 6.99-6.97 (dd, J = 1.5 Hz, J' = 
2.1 Hz, IH, CHCCHO). l3c NMR (75 MHz, CDCI) (5 178.9, 132.6, 126.3, 122.3, 98.8. 
MS (+EI) mlz 173 (M+, 100%), 144 (18.4%), 117 (8.5%), 95 (9.4%), 65 (12.4%), 44 
(5.0%). HRMS (EI) calculated for Cs~BrNO: 172.94762, found 172.94744. 
33: white powder, Rf = (0.20, hexanesltetrahydrofuran), mp 157-159 °c Dit.93 
155-156 °C]. IH NMR (300 MHz, CDCb) (5 10.44 (br s, IH, NID, 9.35 (s, IH, CHO), 
6.98-6.97 (d, J = 1.2 Hz, IH). l3c NMR (75 MHz, CDCb) t5 177.7, 133.1, 123.0, 113.1, 
101.9. MS (+EI) mlz 253 (M+, 100%),224 (12.9%), 197 (7.9%), 173 (4.0%), 144 (7.3%), 
117 (15.7%), 93 (4.7%), 79 (3.6%), 64 (12.7%), 52 (3.1%). HRMS (EI) calculated for 
CsH3Br2NO: 250.85814, found 250.85726. 
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4.2.10 Synthesis of (Z)-2-bromo-5-( (3,5-dimethyl-2H -pyrrol-2-ylidene )methyl)-IH-
pyrrole hydrobromide (36)26 
31 (100 mg, 0.575 mmol) and 2,4-dimethylpyrrole (59.2 ,.d, 0.575 mmol) were 
dissolved in absolute ethanol (3.5 ml) and cooled to 0 0c. Hydrobromic acid (98.8 J.ll, 
0.891 mmol) was added dropwise and this wac;; stirred for 1 h. The mixture was filtered 
using a Hirsch funnel and the precipitate was washed with cold ethanol to yield 36 (63:0 
mg, 0.185 mmol, 32%). 
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Bright orange powder, Rf= (0.50, hexanes/diethyl ether 3:2). IH NMR (600 MHz, 
CDC b) 0 13.89 (br m, 2H, 2xNH), 7.12 (s, IH), 7.07-7.06 (dd, J = 3.0 Hz, J' = 3.0 Hz, 
IH), 6.52-6.51 (d, J = 3.0 Hz, IH), 6.32 (s, 1H), 2.76 (s, 3H, CH3), 2.40 (s, 3H, Clli). I3C 
NMR (75 MHz, CDCh) 0 162.5, 150.3, 133.3, 129.7, 128.2, 124.9, 123.9, 120.2, 118.4, 
15.1, 12.4. MS (+FAB) mlz 251 ([MHt, 100%), 214 (9.9%), 171 (34.4%), 144 (7.3%), 
102 (74.1%). HRMS (FAB) calculated for CllH12BrN2+: 251.01838, found 251.02037. 
Br 
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4.2.11 Synthesis of (Z)-2,3-dibromo-5-«3,5-dimethyJ-2H-pyrro)-2-ylidene)methyJ)-
IH-pyrroJe hydrobromide (37)26 
33 (110 mg, 0.433 mmol) and 2,4-dimethylpyrrole (44.6 J.d, 0.433 mmol) were 
dissolved in absolute ethanol (3 ml) and cooled to 0 °C. Hydrobromic acid (73.0 ,.ll, 
0.671 mmol) W&'i added drop wise and this was stirred for 1 h. The mixture W&'i filtered 
using a Hirsch funnel and the precipitate wa') washed with cold ethanol to yield 37 (69.3 
mg, 0.169 mmol, 39%). 
Bright reddish orange powder, Rf = (0.45, hexanesldiethyl ether 3:2). IH NMR 
(300 MHz, CDCh) 0 14.12 (br m, 2H, 2xNl!), 7.06 (s, IH), 7.02 {s, IH), 6.35 {s, IH), 
2.77 (s, 3H, Clli), 2.39 (s, 3H, CH3). I3C NMR (75 MHz, CDCh) 0 164.4, 151.1, 130.3, 
127.3, 125.5, 120.9, 15.3, 12.4. MS (+FAB) mlz 331 ([MHt, 100%), 307 (13.3%), 251 
(7.8%), 171 (21.7%), 136 (20.2%), 89 (10.2%), 55 (8.2%). HRMS (FAB) calculated fDr 
C llH IlBr2N2+: 328.92890, found 328.92960. 
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4.2.12 Synthesis of 7 -bromo-S,S-difluoro-l,3-dimethyl-SH-dipyrrolo[I,2-c:l ',2'-
f][1,3,2]diazaborinin-4-ium-S-uide (40)26 
To a solution of 36 (100 mg, 0.301 mmol) in toluene (15 ml) wa~ added boron 
trifluoride diethyl etherate (191 Ill, 1.51 mmol) and DBU (135 Ill, 0.904 mmol). The 
resulting mixture wa~ heated to 90°C for 2 h. Afterward, the solution was wa~hed with 
water and the crude material was purified via silica gel chromatography (hexanes/diethyl 
ether 3:2) to give desired fluorophore 40 (53.4 mg, 0.178 mmol, 59%). 
Red lustrous needles, Rf = (0.20, hexanes/diethyl ether 3:2), mp 166°C. Arnax 
excitation in ethanol = 504 nm (Es04 = 68 ()()() M-'cm-'), Amax emission in ethanol = 511 
nm. 'H NMR (300 MHz, CDCh) B 7.03 {s, IH), 6.80-6.79 (d, J = 3.9 Hz, IH),6.38-6.37 
(d, J = 3.9 Hz, IH), 6.16 (s, IH), 2.58 (s, 3H, CH3), 2.23 (s, 3H, CH3). l3C NMR (75 
MHz, CDCh) B 163.9, 145.9, l36.5, l33.6, 126.8, 125.0, 123.0, 121.9, 119.6, 15.2, 11.3. 
MS (+EI) m/z 298 (M+, 67.2%),278 ({M-HFt, 25.3%), 238 (38.5%), 219 (47.3%), 204 
(30.7%), 192 (100%), 144 (17.8%), 119 (45.0%), 76 (32.4%), 65 (9.8%), 51 (12.4%). 
HRMS (EI) calculated for C11HlOBBrF2N2: 298.00885, found 298.00928. 
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4.2.13 Synthesis of 7 ,8-dibromo-S,S-difluoro-l,3-dimethyl-SH -dipyrrolo[I,2-c:l ',2'-
f][1,3,2]diazaborinin-4-ium-S-uide (41)26 
To a solution of 37 (65.0 mg, 0.158 mmol) in toluene (10 ml) was added boron 
trifluoride diethyl etherate (100 ~l, 0.791 mmol) and DBU (71.0 ~l, 0.475 mmol). The 
resulting mixture wa.'S heated to 90°C for 2 h. Afterward, the solution was wa.'Shed with 
water and the crude material wa.~ purified via chromatography (hexanes/diethyl ether 3:2) 
to give desired fluorophore 41 (33.0 mg, 0.087 mmol, 55%). 
Red lustrous needles, Rf = (0.15, hexanes/diethyl ether 3:2), mp 204-206 °C. !..max 
excitation in ethanol = 512 nm (E512 = 42 000 M-1cm-J), Amax emission in ethanol = 524 
nm. IH NMR (300 MHz, CDCh) B 6.98 (s, IH), 6.83 (s, IH), 6.22 (s, IH), 2.60 (s, 3H, 
CH3), 2.26 (s, 3H, CH3). I3C NMR (75 MHz, CDCh) B 166.2, 147.2, 137.2, 132.5, 125.7, 
124.9, 122.7, 122.7, 122.3, 15.4, 11.5 MS (+El) mlz 378 (M+, 62.9%), 358 ([M-HFt, 
14.3%),296 (11.9%), 256 (7.8%), 218 (43.5%), 179 (19.4%), 129 18.9%), 81 (31.8%), 
69 (75.2%), 53 (100%), 43 (63.5%). HRMS (El) calculated for CllH9BBr2F2N2: 
377.91936, found 375.91991. 
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4.2.14 Synthesis of 2-(6-bromohexyl)benzo[d][I,3,2]dioxaborole (44)141 
6-Bromo-1-hexene (2.00 g, 12.3 mmol) and catecholborane (1.31 ml, 12.3 mmol) 
were combined and heated to 100 °C for 18 h. 44 (1.45g, 5.12 mmol, 42%) was obtained 
via Kugelrohr distillation (120 °C at 0.1 Torr) and subjected to transesterification 
immediately. 
Clear and colourless liquid, Rf = (0.60, dichloromethane/methanol 7:1). 
4.2.15 Synthesis of 2-(6-bromohexyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (45)141 
To a solution of 44 (1.22 g, 4.31 mmol) in tetrahydrofuran (5 ml) at 0 °C was 
added pinacol (510 mg, 4.31 mmol). The mixture wa"i stirred at 0 °C for 0.5 h and then at 
ambient temperature for 0.5 h. The solvent was removed in vacuo and then hexanes was 
added to the crude mixture and cooled. to 4 °C for overnight to precipitate the catechol 
by-product. After several repetitions of dissolving in hexanes and removal of by-product 
catechol by filtration, pinacol-boronate 45 (750 mg, 2.57 mmol, 60%) wa"i obtained. 
Light yellow oil, Rf = (0.80, dichloromethane/methanol, visualized by 
H2S0,JMeOH). IH NMR (300 MHz, CDCI) 0 3.26-3.22 (t, J = 6.6 Hz, 2H, ClliBr), 
l.71-1.67 (m, 2H), 1.45-1.38 (m, IH), 1.35-1.18 (m, 4H), 1.07 (m, 14H), 0.64-0.59 (t, J = 
7.2 Hz, IH, CHB(OR)2). I3C NMR (75 MHz, CDCl) 0 82.4, 82.2,33.4,32.4, 3l.0, 27.5, 
24.4, 24.2, 23.4. MS (+EI) mlz 291 ([MH]\ 41.7%), 275 (27.5%), 227 (37.2%), 171 
(18.1 %), 157 (25.3%), 129 (94.9%),83 (89.9%),55 (81t8%), 41 (100%). 
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4.2.16 Synthesis of triphenyl( 6-( 4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-
yl)hexyl)phosphonium bromide (46)95 
45 (2.63 g, 9.04 mmol) and triphenylphosphine (2.37 g, 9.04 mmol) were 
dissolved in xylenes (25 ml) and heated to 120°C for 72 h. Wittig salt 46 (2.88 g, 5.20 
mmol, 58%) wac;; azeotroped from diethyl ether and stored in the refrigerator. 
Colourless viscous oil, Rf = (0.55, dichloromethane/methanoI). lH NMR (300 
MHz, CDCh) 0 7.74-7.58 (m, ISH, 15xArH), 3.58-3.47 (m, 2H, CfuP+Ph3), LSI (m, 
4H), 1.38 (m, IH), 1.19-l.l4 (m, 4H), 1.11-1.09 (m, 8H), 0.61-0.56 (t, J = 7.2 Hz, IH, 
CHB(OR)z). 13C NMR (75 MHz, CDCI3) B 134.9, 131.8, 130.4, 118.5, 117.3,82.6,31.4, 
29.9,29.7,24.6,24.5,23.1,22.7,22.1. MS (+ESI) m/z 473 (W, 100%),363 (20.1%). 
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4.2.17 Synthesis of (Z)-tert-butyldimethyl(2,5,7 ,8-tetramethyl-2-(7 -(4,4,5,5-
tetramethyl-l,3,2-dioxaborolan-2-yl)hept-l-enyl)chroman-6-yloxy)silane (48)95 
Wittig salt 46 (850 mg, 1.54 mmol) was dissolved in tetrahydrofuran (10 m!) 
under nitrogen and to this was added drop wise a 1.0 M solution of potassium tert-
butoxide (188 mg, 1.68 mmoI) in tetrahydrofuran. After stirring for 1 h, a solution of 
rac-Trolox aldehyde (486.7 mg, 1.40 mmol) in tetrahydrofuran (8.5 ml) was added and 
stirred for 16 h. The reaction was then quenched with saturated ammonium chloride 
solution and extracted with dichloromethane. The crude material was subjected to 
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chromatography (dichloromethane/hexanes 1:1) to afford 48 (428 mg, 0.785 mmol, 
56%). 
Dark brown oil, Rf = (0.60, dichloromethane/hexanes 2:1). 1H NMR (300 MHz, 
CDCI3) 05.35 (m, IH, C=CID, 5.28 (m, IH, C=CH), 2.58-2.57 (t, J = 4.8 Hz, 2H), 2.22-
2.06 (m, 12H), 1.88-1.74 (m, IH), 1.51 (m, 2H), 1.42 (s, 3H, Cfu), 1.28 (m, I-OH), 1.10 
(s, 9H, C(Clli)3), 0.81 (t, J = 7.2 Hz, 2H, CHB(OR)2), 0.17 (s, 6H, Si(Cllih). I3C NMR 
(75 MHz, CDCh) 0 146.0, 144.0, 133.1, 132.4, 125.6, 123.3, 122.7, 117.7, 82.6, 75.4, 
33.3, 32.1,29.7,27.8,27.1,26.0,24.7,23.9,21.2,20.4, 18.5, 14.2, 13.3, 11.9, -3A. MS 
(+EI) m/z 542 (M+, 2.1 %), 378 (1.3%), 348 (100%), 319 (63.7%), 221 33.7%), 129 
(28.0%), 85 (18.0%), 73 (55.3%), 43 (30.3%). 
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4.2.18 Synthesis of tert-butyldimethyl(2,5,7 ,8-tetramethyl-2-(7 -( 4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)heptyl)chroman-6-yloxy )silane (49)142 
To a solution of 48 (182 mg, 0.335 mmol) in ethyl acetate (15 ml) was added 10% 
Pd on activated carbon (45.0 mg). The air was flushed with hydrogen gas and the 
reaction was stirred for 15 h at 1 atm. Filtration via Celite® followed by removal of 
solvent in vacuo yielded 49 (174 mg, 0.315 mmol, 100% completion, 94% recovered) . . 
Colourless oil, Rf = (0.50, dichloromethane/hexanes 1:1). 1H NMR (300 MHz, 
CDCI3) 02.59-2.54 (t, J = 6.6 Hz, 2H), 2.12 (s, 3H, Ar-Cfu), 2.09 (s, 3H, Ar-CH3), 2.07 
(s, 3H, Ar-Cfu), 1.85-1.74 (m, 2H), 1.63-1.52 (m, 2H), 1.47-1.41 (m, 5H), 1.31 (m,5H), 
1.26 (m, llH), 1.24 (s, 3H), 1.07 (s, 9H, C(Cfuh), 0.82-0.77 (t, J = 7.2 Hz, 2H, 
CHB(OR)z), 0.14 (s, 6H, Si(CH3h). l3C NMR (75 MHz, CDCl]) 0 145.9, 144.0, 125.7, 
8{) 
123.4, 122.6, 117.4, 82.7, 74.4, 39.6, 32.3, 31.5, 30.l, 29.4, 26.1, 24.8, 24.0, 23.8, 23.6, 
20.9, 18.5, 14.3, 13.4, 11.9, -3.4. MS (+El) m/z 544 (M+, 100%), 482 (5.l %), 418 
(14.4%),378 (6.6%), 348 (33.1%), 319 (28.8%),279 (29.3%),263 (9.2%), 221 (28.{)%), 
143 (9.7%), 73 (65.3%), 59 (9.7%). HRMS (El) calculated for C32H57B04Si: 544.41192, 
found 544.41119. 
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4.2.19 Synthesis of hex-5-enyltriphenylphosphonium bromide (51)143 
6-Bromo-l-hexene (2.50 g, 15.3 mmol) and triphenylphosphine (4.83 g, 18.4 
mmol) were dissolved in acetonitrile (40 ml) and wao;; refluxed for 85 h. After removal of 
solvent in vacuo, the remaining acetonitrile was removed as an azeotrope with diethyl 
ether, Wittig salt 51 (6.52 g, 15.3 mmol, 99%) was obtained. 
White hygroscopic powder, Rf= (0.30, dichloromethane/methanoI20:1), mp 122-
125°C. IH NMR (300 MHz, CDCh) 37.83-7.74 (m, 9H, 9xAr-!!) , 7.69-7.63 (m, 6H, 
6xAr-H), 5.69-5.55 (ddt, J = 17.0 Hz, J' = 10.3 Hz, J" = 6.7 Hz, IH, CH=CH2), 4.91-4.81 
(m, 2H, CH=Cfu), 3.78-3.69 (m, 2H), 2.06-1.97 (m, 2H), 1.77-1.67 (m, 2H), 1.65-1.52 
(m, 2H). I3C NMR (75 MHz, CDCh) 3 137.5, 134.9, 133.7, 130.5, 128.6, 118.7, 117.ti, 
115.2, 32.8, 29.2, 22.8, 21.7. MS (+PAB) miz 345 (M+, 100%), 262 (16.9%), 183 
(16.4%),108 (8.2%), 55 (2.9%). 
81 
4.2.20 Synthesis of (Z)-tert-butyl(2-(hepta-l,6-d ienyl)-2,5,7 ,8-tetramethylchroman-6-
yloxy)dimethylsilane (53)143 
Wittig salt 51 (134 mg, 0.316 mmol) was dissolved in tetrahydrofuran (10 ml) 
under nitrogen and to this was added drop wise a 1.0 M solution of LHMDS in 
tetrahydrofuran (502 JlI, 0.502 mmol). After stirring for 1 h, a solution of (S)-Trolox 
aldehyde (100 mg, 0.287 mmol) in tetrahydrofuran {5 ml) was added and stirred for 16 h. 
The reaction wa5 then quenched with saturated ammonium chloride solution and 
extracted with dichloromethane. The crude material was subjected to silica gel 
chromatography (hexanes/tetrahydrofuran 35:1) to afford 53 (98.0 mg, 0.235 mmol, 
82%). 
Colourless oil, Rf = (0.40, hexanes/dichloromethane 3:1). 1H NMR (300 MHz, 
CDCb) 3 5.89-5.75 (ddt, J = 17.0 Hz, J' = 10.3 Hz, 1" = 6.7 Hz, IH, CH=CH2), 5.37 (m, 
2H), 5.05-4.96 (m, 2H, CH=Cfu), 2.59-2.57 (t, J = 6.0 Hz, 2H), 2.42-2.25 (m, 2H), 2.16 
(s, 3H, Ar-C!b), 2.15 (s, 3H, Ar-C!b), 2.09 (s, 3H, Ar-C!b), 2.05-2.00 (m, 2H), 1.85-
1. 75 (m, IH), 1.51 (s, 3H), 1.48-1.31 (m, 3H), 1.09 (s, 9H, C(C!b)3), 0.16 (s, 6H, 
Si(C!b)2). I3C NMR (75 MHz, CDCh) 3146.1, 144.2, 138.7, 132.0, 125.8, 123.5, 122.4, 
117.8, 114.4, 75.5, 33.5, 29.2, 27.3, 26.1, 21.3, 18.6, 14.3, 13.4, 12.2, -3.3. MS (+EI) mlz 
414 (M+, 100%), 278 (56.0%), 221 (37.1%), 187 (7.8%), 73 (85.5%), 59 (15.0%), 41 
(12.8%). HRMS (EI) calculated for C26H4202Si: 414.29541, found 414.29456. 
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4.2.21 Synthesis of (S)-tert-butyJdimethyl(2,S,7,8-tetramethyl-2-vinyIchroman-6-
yloxy)silane (61)142 
Methyltriphenylphosphonium bromide (169 mg, 0.473 mmol) wa'l dissolved in 
tetrahydrofuran (10 ml) under nitrogen and to this was added dropwise a IJ) M soluti()n 
of LHMDS in tetrahydrofuran (753 Ill, 0.753 mmol). After stirring for 1 h, a solution of 
(S)-Trolox aldehyde (150 mg, 0.430 mmol) in tetrahydrofuran (5 ml) was added and 
stirred for 3 h. The reaction was then quenched with saturated ammonium chloride 
solution and extracted with dichloromethane. The crude material was subjected to 
chromatography (hexanes/dichloromethane 3:1) to afford product 61 (132 mg, 0.380 
mmol,88%). 
White solid, Rf = (0.30, hexanesldichloromethane 3:1), mp 54°C. IH NMR (300 
MHz, CDCI3) 0 5.94-5.85 (dd, J = 17.1 Hz, J' = 10.8 Hz, 1H, CH=CH2), 5.20-5.13 (dd, J 
= 17.1 Hz, J' = 1.1 Hz, 1H, CH=Cfu), 5.07-5.03 (dd, J = 10.8 Hz, J' = 1.1 Hz, 1H, 
CH=Cfu), 2.66-2.48 (m, 2H), 2.19 (s, 3H, Ar-Clli), 2.17 (s, 3H, Ar-Cfu), 2.09 (s, 3H, 
Ar-C!b), 2.01-1.81 (m, 2H), 1.44 (s, 3H, C!b), 1.10 (s, 9H, C(C!b)3), 0.17 {s, 6H, 
Si(Cfuh). \3C NMR (75 MHz, CDCh) 0146.0, 144.2, 141.9, 125.8, 123.4, 122.2, 117.5, 
113.1, 75.2, 31.9, 27.0, 26.1, 21.1, 18.6, 14.3, 13.4, 12.0, -3.3. MS (+EI) m/z 346 (M+, 
100%), 331 (8.6%), 289 (12.4%), 278 (27.3%), 234 (10.9%), 221 (49.5%), 163 (9.0%), 
129 (6.7%), 73 (53.8%), 59 (13.6%). HRMS (EI) calculated for C2IH3402Si: 346.23281, 
found 346.23288. 
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4.2.22 Synthesis of oct-7-enoic acid (63)IHl 
To a stirring solution of 7 -bromo-l-heptene (2.00g, 11.3 mmol) in dry diethyl 
ether (10 ml) wac;; added magnesium turnings (302 mg, 12.4 mmol) and a catalytic 
amount of iodine. The mixture was heated to 34°C for 3.5 h and then {;ooled to -20 °C 
upon which carbon dioxide (dry ice subliming through a Drierite® drying tube) was 
bubbled into the solution. After 2 h, the reaction was quenched with 19% hydrochloric 
acid (10 ml) and extracted with diethyl ether. Removal of solvent in vacuo obtained acid 
63 (452 mg, 2.94 mmol, 26%). 
Clear and colourless liquid, Rf = (0.25, hexanes/ethyl acetate 5:1, visualized by 
H2S0,JMeOH). IH NMR (300 MHz, CDCI3) 0 11.79 (br s, IH, C02!!), 5.82-5.73 {ddt, ] 
= 17.0 Hz,]' = 10.3 HZ,]" = 6.7 Hz, IH, CH=CH2), 5.02-4.90 (m, 2H, CH=Cfu), 2.36-
2.31 (t,] = 1.5 Hz, 2H, CfuC02H), 2.08-2.01 (m, 2H, CfuCH=CH2), 1.66-1.61 (m,2H), 
1.43-1.28 (m, 4H). I3C NMR (75 MHz, CDCh) 0 180.3, 138.4, 114.3, 33.9, 33.4, 28.4, 
24.4. MS (+FAB) mlz 143 ([MHt, 20.4%), 137 (15.2%), 125 (28.2%), 107 (9.3%), 97 
(34.0%),81 (16.1%),67 (13.4%), 55 (100%),41 (39.2%). HRMS (FAB) calculated for 
4.2.23a Synthesis of S-pyridin-2-yl but-3-enethioate (90a, n = 1)110 
To a solution of 3-butenoic acid {902 mg, 10.5 mmol) in dry toluene (15 ml) wac;; 
added 2,2' -dipyridyl disulfide (3.00 g, 13.6 mmol) and triphenylphosphine (3.57 g, 13.6 
mmol). This mixture wac;; stirred overnight. After wac;;hing the solution with water and 
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then washing the combined water fractions with diethyl ether, the organic phases were 
combined, condensed in vacuo, and the crude material was loaded onto a silica gel 
column eluting with hexanes/ethyl acetate 6:1 to afford pure thioate 90a (967 mg, 5.36 
mmol,51%). 
Light yellow syrup, Rf = (0.15, hexanes/diethyl ether 3:2). IH NMR (300 MHz, 
CDCh) 0 8.32-8.30 (dd, J = 4.8 Hz, j' = 0.9 Hz, IH), 7.43-7.37 (m, IH), 7.33-7.30 (d, J = 
7.8 Hz, 1H), 6.74-6.93 (m, 1H), 5.74-5.61 (ddt, J = 17.0 Hz, J' = W.1 Hz, j" = 6.9 Hz, 
1H, CH=CH2), 5.01-4.95 (m, 2H, CH=Cfu), 3.17-3.15 (d, J = 6.9 Hz, 2H, CfuCO). l3C 
NMR (75 MHz, CDCh) 0 193.0, 150.4, 149.4, 136.3, 129.2, 128.4, 122.7, 119.5,47.5. 
MS (+EI) m/z 179 (M+, 0.8%),151 (16.6%), 136 (6.0%),111 (100%),78 (41.2%),67 
(24.1%), 51 (13.7%), 41 (45.7%). HRMS (EI) calculated for C9H9NOS: 179.04049, 
found 179.04040. 
4.2.23b Synthesis of S-pyridin-2-yl pent-4-enethioate (90b, n = 2) 
(1.70 g, 8.79 mmol, 88%). Light yellow syrup, Rf = (0.25, hexanesldiethyl ether 
3:2). IH NMR (300 MHz, CDCh) 0 8.42-8.40 (dd, J = 4.8 Hz, J' = 0.9 Hz, 1H), 7.54-7.49 
(m, 1H), 7.43-7.41 (d, J = 7.8 Hz, IH), 7.08-7.04 (m, 1H), 5.71-5.58 (ddt, J = 16.9 Hz, J' 
= 10.4 Hz, J" = 6.6 Hz, 1H, CH=CH2), 4.94-4.83 (m, 2H, CH=Cfu), 2.64-2.59 (t, J = 6.9 
Hz, 2H, CfuCO), 2.31-2.24 (m, 2H, CH.,CH=CH2). 13C NMR (75 MHz, CDCh) B 194.9, 
150.8, 149.7, 136.5, 135.3, 129.5, 122.9, 115.5, 42.6, 28.5. MS (+EI) m/z 193 (M+, 
0.8%), 160 (4.5%), 124 (4.3%), 111 (100%), 78 (11.0%), 67 (14.7%), 55 (43.4%), 41 
(4.3%). HRMS (EI) calculated for CIOHIINOS: 193.05614, found 193.05645. 
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4.2.23e Synthesis of S-pyridin-2-yl hex-5-enethioate (64a, n = 3) 
(1.95 g, 9.42 mmol, 96%). Light yellow syrup, Rf = (0.35, hexanes/diethyl ether 
3:2). IH NMR (300 MHz, CDC!) 0 8.40-8.38 (dd, I = 4.8 Hz, f = 0.9 Hz, IH), 7.52-7.47 
(m, lH), 7.42-7.39 (d, I = 8.1 Hz, IH), 7.06-7.02 (m, IH), 5.61-5.52 (ddt, J = 16.~ Hz, f 
= 10.4 Hz, I" = 6.6 Hz, IH, CH=CH2), 4.88-4.79 (m, 2H, CH=C!:b), 2.53-2.48 (t, I = 7.5 
Hz, 2H, C!:bCO), 1.96-1.89 (m, 2H, C!:bCH=CH2), 1.67-1.57 (m, 2H). I3C NMR (75 
MHz, CDC!) 0 195.4, 150.9, 149.7, 136.6, 136.4, 129.4, 122.8, 115.1,42.7,32.1,23.7. 
MS (+EI) mlz 207 (M+, 0.4%), 179 (1.2%), 166 (3.1%), 125 (4.3%), 111 (100%),78 
(12.2%), 69 (19.4%), 55 (32.5%), 41 (38.2%). HRMS (EI) calculated for CIIH13NOS: 
207.07179, found 207.07210. 
4.2.23d Synthesis of S-pyridin-2-yl hept-6-enethioate (64b, n = 4) 
(1.42 g, 6.43 mmo), 95%). Light yellow syrup, Rf = (0.35, hexanes/diethy) ether 
3:2). IH NMR (300 MHz, CDC!) 8 8.29-8.26 (m, IH), 7.37-7.30 (m, 2H), 6.93-6.89 (m, 
IH), 5.48-5.42 (rn, IH, CH=CH2), 4.74-4.64 (rn, 2H, CH=C!:b), 2.42-2.37 (t, J = 7.5 Hz, 
2H, C!:bCO), 1.79-1.71 (m, 2H, C!:bCH=CH2), 1.47-1.37 (m, 2H), 1.20-1.10 (m, 2H). 
I3C NMR (75 MHz, CDCh) 8 194.8, 150.8, 149.3, 137.1, 136.0, 128.9, 122.4, 113.9, 
42.9, 32.3, 27.0, 23.8. MS (+EI) mlz 221 (M+, 0.2%), 188 (1.1 %), 160 (3.1%), 125 
(2.7%), 111 (100%), 78 (10.0%), 67 (13.9%), 55 (31.1%), 41 (23.8%). HRMS (EI) 
calculated for CI2HISNOS: 221.08744, found 221.08726. 
4.2.23e Synthesis of S-pyridin-2-yl oct-'-enethioate (64e, n = 5) 
(733 mg, 3.45 mmol, 98%). Light yellow syrup, Rf = (0.35, hexanes/diethyl ether 
3:2). IH NMR (300 MHz, CDC!) 0 8.36-8.34 (dd, I = 4.8 Hz, J' = 1.2 Hz, IH), 7.47-7.36 
(m, 2H), 7.01-6.96 (m, IH), 5.59-5.50 (ddt, J = 16.8 Hz, I' = 10.2 Hz, J" = 6.6 Hz, IH, 
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CH=CH2), 4.80-4.69 (m, 2H, CH=Cfu), 2.47-2.43 (t, J = 7.5 Hz, 2H, CfuCO), 1.84-1.77 
(m, 2H, CfuCH=CH2), 1.53-1.43 (m, 2H), 1.22-1.09 (m, 4H). 13C NMR (75 MHz, 
CDCh) 0 195.2, 151.0, 149.5, 137.8, 136.3, 129.2, 122.7, 113.8, 43.3, 32.7, 27.7, 27.5, 
24.4. MS (+EI) mlz 235 (M+, 0.8%), 174 (2.2%),125 (2.7%), III (100%), 78 (10.3%), 67 
(13.0%), 55 (43.7%), 41 (15.1 %). HRMS (EI) calculated for C13HJ7NOS: 235.10309, 
found 235.10277. 
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4.2.24a Synthesis of 1-(lH-pyrrol-2-yl)but-3-en-1-one (91a, n = 1)110 
Pyrrole (1.49 ml, 21.4 mmol) was dissolved in tetrahydrofuran (7 ml) and cooled 
to 0 °C under nitrogen. To this was slowly added a 3.0 M solution of methylmagnesium 
chloride in tetrahydrofuran (5.36 ml, 16.1 mmol) and the resulting solution was stirred for 
15 min. Next, the solution was cooled further to -78°C and a solution of thioate 90a 
(960 mg, 5.36 mmol) in tetrahydrofuran (30 ml) was added. The reaction was stirred for 
1 h. Afterward, the reaction mixture was condensed in vacuo and then extracted with 
dichloromethane. This crude material wac; purified via column chromatography 
(hexanes/diethyl ether 3:2) to yield ketopyrrole 91a (476 mg, 3.52 mmol, 66%). 
Clear and colourless oil, Rf = (0.30, hexanesldiethyl ether 3:2). IH NMR (300 
MHz, CDCh) 0 10.65 (br s, IH, NH), 7.10-7.07 {m, IH), 7.00-6.97 (m, IH), 6.29-6.26 
(m, IH), 6.14-6.01 (ddt, J = 17.0 Hz, J' = 10.1 Hz, J" = 6.9 Hz, IH, CH=CH2), 5.27-5.26 
(m, IH, CH=C!h), 5.23-5.18 (m, IH, CH=CH?), 3.60-3.57 (dt, J = 7.0 Hz, J' = 1.5 Hz, 
2H,Cfu). I3CNMR(75MHz,CDCh)0 188.4,131.5,131.2,125.6,118.2,117.1, lW.4, 
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42.9. MS (+EI) m/z 135 (M+, 18.3%),94 (100%), 66 (21.6%), 39 (17.6%). HRMS (EI) 
calculated for CgH9NO: 135.06841, found 135.06821. 
4.2.24b Synthesis of l-(lH-pyrrol-2-y)pent-4-en-l-one (9lb, n = 2) 
(1.27 g, 8.53 mmol, 97%). Clear and colourless oil, Rr = (0.35, hexanes/diethyl 
ether 3:2). JH NMR (300 MHz, CDCh) 611.02 (hr s, IH, NH), 7.12-7.10 (m, IH), 7.01-
6.97 (m, IH), 6.31-6.28 (m, IH), 6.01-5.87 (ddt, J = 17.0 Hz, J' = 10.1 Hz, J" = 6.9 Hz, 
IH, CH=CH2), 5.24-5.03 (m, 2H, CH=Clli), 3.00-2.92 (t, J = 7.2 Hz, 2H, ClliCO), 2.59-
2.55 (m, 2H, ClliCH=CH2). I3C NMR (75 MHz, CDCh) 6 190.2, 137.1, 131.6, 125.4, 
116.7, 114.9, 110.1,36.8,28.8. MS {+EI) mlz 149 (M+, 23.1 %), 134 (1.9%), 120 (1.8%), 
107 (3.3%), 94 (100%), 80 (5.9%), 66 (15.3%), 53 (3.6%), 44 (4.2%). HRMS (EI) 
calculated for C9HIINO: 149.08406, found 149.08420. 
4.2.24c Synthesis of l-(lH-pyrro)-2-y)hex-5-en-l-one (65a, n = 3) 
(356 mg, 2.17 mmol, 90%). Clear and colourless oil, Rf = (0.40, hexanes/diethyl 
ether 3:2). IH NMR (300 MHz, CDCh) 6 10.29 (hr s, IH, NH), 7.06 (m, IH), 6.93 (m, 
1H), 6.27-6.26 (m, IH), 5.89-5.76 (ddt, J = 17.0 Hz, J' = 10.1 Hz, J" = 6.9 Hz, IH, 
CH=CH2), 5.07-4.98 (m, 2H, CH=Clli), 2.82-2.77 (t, J = 7.2 Hz, 2H, ClliCO), 2.18-2.11 
(m, 2H, CH,CH=CH2), 1.89-1.80 (m, 2H). I3C NMR (75 MHz, CDCh) 6 191.0, 138.0, 
131.9, 124.9, 116.4, 115.1, 110.4, 37.1,33.2, 24.3. MS (+EI) mlz 163 (M+, 25.3%), 146 
(1.1 %), 122 (1.6%), 109 (100%), 94 (63.0%), 80 (6.7%), 66 (14.9%), 55 (5.1 %), 44 
(15.4%). HRMS (EI) calculated for ClOH13NO: 163.09971, found 163.09972. 
4.2.24d Synthesis of l-(lH-pyrrol-2-yJ)hept-6-en-l-one (65b, n = 4) 
(1.11 g, 6.23 mmol, 97%). Clear and colourless oil, Rf = (0.45, hexanes/diethyl 
ether 3:2). JH NMR (300 MHz, CDCh) 6 11.21 (hr s, IH, NH), 7.12-7.1 0 (m, IH), 6.99-
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6.98 (m, IH), 6.31-6.28 (m, IH), 5.91-5.80 (ddt, J = 17.0 Hz, j' = 10.3 Hz, J" = 6.7 Hz, 
IH, CH=CH2), 5.12-5.01 (m, 2H, CH=Cfu), 2.87-2.82 (t, J = 7.2 Hz, 2H, CfuCO), 2.18-
2.11 (m, 2H, CfuCH=CH2), 1.88-1.77 (m, 2H), 1.58-1.48 (m, 2H). I3C NMR (75 MHz, 
CDCl)) 0 191.0, 138.1, 131.6, 125.2, 116.6, 114.2, 109.9, 37.3, 33.2, 28.2, 24.5. MS 
(+EI) m/z 177 (M+, 21.8%), 149 (2.1%), 134 (2.2%), 122 (25.9%), 109 (91.7%), 94 
(100%), 80 (6.8%), 67 (36.2%), 55 (11.9%), 41 (15.4%). HRMS (EI) calculated for 
CIlH15NO: 177.11536, found 177.11487. 
4.2.24e Synthesis of 1-(lH-pyrrol-2-yl)oct-7-en-l-one (65c, n = 5) 
(551 mg, 2.88 mmol, 93%). Clear and colourless oil, Rf = (0.45, hexanes/diethyl 
ether 3:2). lH NMR (300 MHz, CDCh) 010.81 (br s, IH, N!!), 7.09-7.06 (m, IH), 6.97-
6.94 (m, IH), 6.28-6.26 (m, IH), 5.87-5.78 (ddt, J= 17.0 Hz, j' = 10.3 Hz, J" = 6.7 Hz, 
IH, CH=CH2), 5.05-4.95 (m, 2H, CH=Cfu), 2.83-2.78 (t, J = 7.2 Hz, 2H, CH2CO), 2.11-
2.04 (m, 2H, CH,CH=CH2), 1.80-1.75 (m, 2H), 1.48-1.39 (m, 4H). J3C NMR (75 MHz, 
CDCh) 0191.3, 138.6, 131.8, 125.2, 116.5, 114.2, 110.1,37.7,33.4,28.7, 28.S, 25.1. MS 
(+EI) m/z 191 (M+, 20.8%), 148 (2.2%), 136 (1.7%), 122 (18.5%), 109 (100%), 94 
(77.5%), 80 (8.1 %), 67 (19.6%), 55 (8.9%), 41 (10.1%). HRMS (EI) calculated for 
C12H17NO: 191.13101, found 191.13106. 
4.2.25a Synthesis of 2-(pent-4-enyl)-lH-pyrrole (92, n = 2)110 
Ketopyrrole 91b (320 mg, 2.37 mmol) was dissolved in iso-propanol (6 mt) and 
heated to reflux. To this boiling solution wac;; added a suspension of sodium borohydride 
(251 mg, 6.63 mmol) in iso-propanol (4 ml). The reflux went overnight. Afterward, the 
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crude material was condensed in vacuo and pa">sed through a neutral alumina column 
(hexanes/ethyl acetate 10:1) to afford crude 92 that was reacted immediately in the next 
step. Note: extreme care must be used when handling these alkenyl pyrroles for they 
readily decompose, especially in the presence of an acid, and must be used immediately. 
Clear and colourless liquid, fruity odour, Rf = (0.50, hexanesletbyl acetate 6:1, 
alumina). 
4.2.2Sb Synthesis of 2-(hex-S-enyl)-lH-pyrrole (66a, n = 3) 
Clear and colourless liquid, fruity odour, Rf = (0.50, hexaneslethyl acetate 6:1, 
alumina). 
4.2.2Sc Synthesis of 2-(hept-6-enyl)-lH-pyrrole (66b, n = 4) 
Clear and colourless liquid, fruity odour, Rf = (0.60, hexanes/ethyl acetate 6: 1, 
alumina). 
4.2.2Sd Synthesis of 2-(oct-7-enyl)-lH-pyrrole (66c, n = 5) 
Clear and colourless liquid, fruity odour, ~f = (0.60, hexaneslethyl acetate 6: 1, 
alumina). 
4.2.26a Synthesis of 7-(hex-5-enyl)-S,S-difluoro-l,3-dimethyl-SH-dipyrrolo[1,2-
c:l',2'-f][1,3,2]diazaborinin-4-ium-5-uide (58a, n = 3)46 
Crude 66a and 3,5-dimethylpyrrole-2-carboxaldehyde (70.0 mg, 0.568 mmol) 
were dissolved in dry dichloromethane (8.5 ml) and cooled to 0 °C under nitrogen. A 
solution of phosphorus oxychloride (52.0 ,.d, 0.568 mmol) in dichloromethane (0.5 ml) 
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was added via syringe and the resulting solution was kept on ice for 1 h. Afterward, the 
reaction Wa's brought to room temperature and stirred overnight. This solution was then 
cooled back to 0 °C and boron trifluoride diethyl etherate (288 Ill, 2.27 mmol) and 
DIPEA (396 Ill, 2.27 mmol) were added. After warming back to room temperature and 
stirring for 6 h, the crude product was extracted in dichloromethane and condensed ill 
vacuo. Purification by silica gel chromatography (hexanesldiethyl ether 3:1) afforded 
pure 58a (143 mg, 0.476 mmol, 40% over two steps). 
Dark red oil, Rf = (0.30, hexanes/diethyl ether 3:2). Amax excitation in ethanol = 
507 nm (£507 = 87 000 M"lcm·'), Amax emission in ethanol = 511 nm. IH NMR (300 MHz, 
CDCh) 07.04 (s, IH), 6.89-6.87 (d, J = 3.9 Hz, IH), 6.28-6.26 {d, J = 3.9 Hz, IH), 6.07 
(s, 1H), 5.89-5.76 (ddt, J = 17.0 Hz, J' = 10.3 Hz, J" = 6.7 Hz, 1H, CH=CH2), 5.05-4.94 
(m, 2H, CH=Clli), 3.01-2.96 (t, J = 7.8 Hz, 2H, BDP-CH2), 2.55 (s, 3H, BDP-Cfu), 2.21 
(s, 3H, BDP-CH3), 2.16-2.09 (m, 2H, CH?CH=CH2), 1.81-1.70 (m, 2H), 1.58-1.48 (m, 
2H). l3C NMR (75 MHz, CDCh) 0 160.5, 142.9, 138.7, 134.6, 133.3, 128.4, 123.4, 
119.8, 118.9, 116.7, 114.5, 33.5, 28.7, 28.4, 28.0, 14.8, 11.2. llB NMR (193 MHz, 
CDCh) 1.11-0.77 (t, J = 32.7 Hz, BF2). 19F NMR (282 MHz, CDCb) -145.2 - -145.5 
(overlapping q and sextet, J = 33.3 Hz, B5). MS (+EI) mlz 302 (M+, 50.3%), 282 ([M-
HFt, 3.5%), 248 (11.6%), 233 (100%), 213 (24.1%), 195 (7.5%), 149 (19.3%),111 
(12.9%), 97 (8.6%), 83 (9.6%), 71 (12.9%), 57 (22.7%), 43 (17.7%). HRMS (EI) 
calculated for CI7H2IBF2N2: 302.17659, found 302.17684. 
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4.2.26b Synthesis of 7 -(hept-6-enyl)-5,5-difluoro-l,3-dimethyl-5H -dipyrrolo[1,2-
e:l' ,2' -f][1,3,2]diazaborinin-4-ium-5-uide (5Sb, n = 4) 
(313 mg, 0.988 mmol, 34% over two steps). Dark red oil, Rf = (0.45, 
hexanes/diethyl ether 3:2). Amax excitation in ethanol = 507 nm (£507 = 86 000 M·1cm-\ 
"'max emission in ethanol = 511 nm. lH NMR (300 MHz, CDCb) S 7.00 (s, IH), 6.84-
6.83 (d, J = 3.9 Hz, IH), 6.25-6.23 (d, J = 3.9 Hz, 1H), 6.02 (s, IH), 5.88-5.75 {ddt, J = 
17.0 Hz, J' = 10.3 Hz, J" = 6.7 Hz, IH, CH=CH2), 5.05-4.92 (m, 2H, CH=CH,), 3.00-
2.95 (t, J = 7.8 Hz, 2H, BDP-Cfu), 2.53 (s, 3H, BDP-C!b), 2.15 (s, 3H, BDP-C!b), 2.08-
2.04 (m, 2H, CfuCH=CH2), 1.79-1.69 (m, 2H), 1.48-1.43 (m, 4H). 13C NMR (75 MHz, 
CDCh) S 160.3, 158.6, 142.7, 138.7, 134.4, 133.2, 128.4, 123.3, 119.6, 116.5, 114.1, 
33.5,28.9,28.5,28.4,28.3, 14.6, 10.9. lIB NMR (96 MHz, CDCb) 1.29-0.60 (t, J = 32.7 
Hz, BF2)' 19F NMR (282 MHz, CDCb) -144.7 - -145.1 (overlapping q and sextet, J = 
33.3 Hz, BEz). MS (+EI) m/z 316 (M+, 49.0%), 277 (2.1 %), 248 (61.2%), 233 (100%), 
213 (23.0%), 194 (4.3%), 149 (3.9%), 116 (9.9%), 81 (4.2%),69 (7.6%), 55 (7.5%), 43 
(13.2%). HRMS (EI) calculated forClsH23BF2N2: 316.19224, found 316.19279. 
4.2.26e Synthesis of 7 -(oct-7 -enyl)-5,5-difluoro-l,3-dimethyl-5H-dipyrrolo[1,2-
e:l' ,2'-f][1,3,2]diazaborinin-4-ium-5-uide (SSe, n = 5) 
(370 mg, 1.12 mmol, 39% over two steps). Dark red oil, Rf = (0.50, 
hexanes/diethyl ether 3:2). "'max excitation in ethanol = 507 nm (£507 = 85 000 M-Icm-I), 
"'max emission in ethanol = 511 nm. lH NMR (300 MHz, CDCh) S 7.02 (s, IH), 6.87-
6.85 (d, J = 3.9 Hz, 1H), 6.26-6.25 (d, J = 3.9 Hz, IH), 6.04 (s, IH), 5.89-5.75 (ddt, J = 
17.0 Hz, l' = 10.3 Hz, J" = 6.7 Hz, IH, CH=CH2), 5.02-4.92 (m, 2H, CH=Cfu), 3.00-
2.95 (t, J = 7.8 Hz, 2H, BDP-CH?), 2.54 (s, 3H, BDP-C,lli), 2.18 (s, 3H, BDP-CH3), 2.07-
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2.02 (m, 2H, ClliCH=CH2), 1.78-1.69 (m, 2H), 1.52-1.40 (m, fiH). I3C NMR (75 MHz, 
CDCh) () 160.6, 158.7, 142.7, 139.0, 134.5, 133.2, 128.4, 123.4, 119.7, 116.6, 114.1, 
33.7,29.3,28.8,28.7,28.6,28.5,14.7,11.0. lIB NMR (96 MHz, CDCh) 1.29-0.60(t, J = 
32.7 Hz, BF2). 19F NMR (282 MHz, CDCh) -144.9 - -145.3 (overlapping q and sextet, J 
= 33.3 Hz, B5). MS (+El) m/z 330 (M+, 10.2%),248 (100%), 233 (40.5%), 218 (15.4%), 
149 (10.6%), 116 (15.3%), 94 (10.9%), 83 (7.9%), 69 (14.3%), 57 (1.6.0%),44 (40.8%). 
HRMS (El) calculated for C19H25BF2N2: 330.20789, found 330.2D818. 
4.2.27a Synthesis of (S,E)-7 -( 6-( 6-(tert-butyldimethylsilyloxy)-2,5,7 ,8-
tetramethylchroman-2-yl)hex-5-enyl)-5,5-difluoro-l,3-dimethyl-5H -dipyrrolo[I,2-
c:l' ,2'-f][1,3,2]diazaborinin-4-ium-5-uide (68a, n = 3)43 
Vinyl Trolox 61 (61.9 mg, 0.179 mmol) and hexenylBODlPY 58a (lOS mg, 0.357 
mmol) were dissolved in dry dichloromethane (1.5 ml). Grubbs Catalyst 2nd Generation 
59 (15.2 mg, 0.018 mmol) was then added and the reaction refluxed for 6 h. The mixture 
wa~ condensed in vacuo and the crude residue was loaded Dnto a silica column 
(hexanes/diethyl ether 6: 1) to obtain 68a (72.3 mg, 0.117 mmol, 65%). 
Dark red oil, Rf= (0.50, hexanes/diethyl ether 3:2). IH NMR (300 MHz, CDCh) 
() 7.05 (s, IH), 6.89-fi.S8 (d, J = 3.9 Hz, IH), 6.21-6.19 (d, J = 3.9 Hz, IH), 6.08 (s, IH), 
5.54-5.50 (m, 2H, CH=CH), 2.96-2.91 (t, J = 7.8 Hz, 2H, BDP-Cfu), 2.56-2.50 (m, 5H, 
C4-Cfu, BDP-CH3), 2.24 (s, 3H, Ar-Cfu), 2.14 (s, 3H, BDP-Cfu), 2.12 (s, 3H, Ar-Cfu), 
2.03 (s, 3H, Ar-Cfu), 2.07-2.oo{m, IH, C3-CH), 1.94-1.71 (m, 3H, C3-CH, Cfu), 1.68-
93 
1.60 (m, 2H), 1.46-1.40 (m, 2H), 1.38 (s, 3H, Cfu), 1.07 (s, 9H, CCCH3)3), 0.14 (s, 6H, 
Si(Clli)2). l3C NMR (75 MHz, CDCh) 0160.7, 158.9, 146.1, 144.1, 142.8, 134.6, 134.2, 
133.3, 128.6, 128.5, 128.3, 125.7, 123.4, 122.2, 119.8, 117.7, 116.8, 74.8, 32.3, 31.9, 
29.0, 28.4, 27.8, 27.3, 26.1, 21.2, 18.6, 14.8, 14.3, 13.4, 12.0, i1.2, -3.4. llB NMR (96 
MHz, CDCI3) 1.27-0.58 (t, J = 32.7 Hz, BF2). 19F NMR (282 MHz, CDCh) -145.0 - -
145.5 (overlapping q and sextet, J = 33.3 Hz, B5). MS (+EI) mlz 620 (M+, 0.6%), 378 
(1.3%),346 (13.2%), 316 (26.8%), 278 (6.1 %), 233 (100%), 213 (25.4%), 149 (25.3%), 
129 (6.5%), 97 (11.0%), 83 (20.2%),71 (32.7%),57 (54.0%), 43 (78.6%). HRMS (EI) 
calculated for C36H51BF2N202Si: 620.37810, found 620.37428. 
4.2.27b Synthesis of (S,E)-7 -(7 -( 6-(tert-butyldimethylsilyloxy)-2,S,7 ,8-
tetramethylchroman-2-yl)hept-6-enyl)-S,S-difluoro-l,3-dimetbyl-SH-dipyrrolo[1,2-
c:l',2'-f][1,3,2]diazaborinin-4-ium-S-uide (68b, n = 4) 
(61.8 mg, 0.097 mmol, 53%). Dark red oil, Rf = (0.55, hexanes/diethyl ether 3:2). 
IH NMR (300 MHz, CDCh) 07.08 (s, IH), 6.92-6.90 (d, J = 3.9 Hz, IH), 6.29-6.28 (d, J 
= 3.9 Hz, 1H), 6.10 (s, IH), 5.54-5.51 (m, 2H, CH=C!D, 2.99-2.94 (t, J = 7.8 Hz, 2H, 
BDP-C!h), 2.58 (s, 3H, BDP-Cfu), 2.56-2.49 (m, 2H, C4-C!h), 2.26 (s, 3H, Ar-CH3), 
2.16 (s, 3H, BDP-Cfu), 2.14 (s, 3H, Ar-Cfu), 2.00 (s, 3H, Ar-Cfu), 1.96-1.54 (m, 6H), 
1.51-1.39 (m, 4H), 1.39 (s, 3H, Cfu), 1.07 (s, 9H, CCCfu)3), 0.13 (s, 6H, Si(Cfuh). \3e 
NMR (75 MHz, CDCh) 0 160.8, 158.9, 146.1, 144.1, 142.8, 134.6, 134.2, 133.3, 128.8, 
128.6, 128.5, 125.7, 123.4, 122.2, 119.8, 117.7, 116.8, 74.7, 32.4, 32.0, 29.0, 28.8, 28.6, 
28.4,27.2,26.1,21.2,18.6, 14.8, 14.3, 13.4,12.0,11.2, -3.4. llB NMR (96 MHz, CDC h) 
1.30-0.61 (t, J = 32.7 Hz, BF2). 19p NMR (282 MHz, CDCb) -144.9 - -145.5 
(overlapping q and sextet, J = 33.3 Hz, BF,). MS (+EI) mlz 634 (M+, 0.1%), 422 (1.2%), 
94 
346 (20.7%), 278 (11.6%), 233 (100%), 213 (24.6%), 195 (3.8%), 149 (11.4%), 116 
(2.6%), 73 (11.5%), 41 (7 .9%). HRMS (EI) calculated for C37H53BF2N202Si: 634.39375, 
found 634.39555. 
4.2.27c Synthesis of (S,E)-7 -(8-( 6-(tert-butyldimethylsilyloxy)-2,S,7 ,8-
tetramethylchroman-2-yl)oct-7 -enyl)-S,5-difluoro-l,3-dimethyl-5H -dipyrrolo[l,2-
c:l',2'-f][l,3,2]diazaborinin-4-ium-5-uide (68c, n = 5) 
(174 mg, 0.268 mmol, 48%). Dark red oil, Rf = (0.55, hexanesldiethyl ether 3:2). 
IH NMR (300 MHz, CDC13) 07.05 (s, IH), 6.90-6.89 (d, J = 3.9 Hz, IH), 6.29-6.28 (d, J 
= 3.9 Hz, IH), 6.08 (s, IH), 5.53-5.50 (m, 2H, CH=CID, 3.00-2.95 (t, J = 7.8 Hz, 2H, 
BDP-C!i2), 2.57-2.49 {m, 5H, C4-CH", BDP-C!b), 2.23 (s, 3H, Ar-C!b), 2.16 (s, 3H, 
BDP-CH3), 2.14 (s, 3H, Ar-Clli), 2.06 (s, 3H, Ar-Clli), 2.02-1.67 (m, 6H), 1.46-1.32 (m, 
6H), 1.39 (s, 3H, CH3), 1.07 (s, 9H, C(Clli)3), 0.14 (s, 6H, Si(CH3h). 13C NMR (75 
MHz, CDCh) 0 160.8, 158.8, 146.1, 144.0, 142.7, 134.5, 133.9, 133.3, 128.8, 128.5, 
128.4, 125.6, 123.4, 122.1, 119.7, 117.6, 116.7, 74.7, 32.3, 32.1, 29.1, 28.9, 28.7, 28.6, 
28.5,27.2,26.1,21.1, 18.5, 14.7,14.3, 13.4,12.0,11.1, -3.4. liB NMR (96 MHz, CDCh) 
1.31-0.62 (t, J = 32.7 Hz, BF2). 19F NMR (282 MHz, CDCh) -145.0 - -145.4 
(overlapping q and sextet, J = 33.0 Hz, B5). MS (+EI) mlz 648 (M+, 0.8%),406 (11.8%), 
344 (23.8%), 233 (100%), 213 (26.2%), 194 (3.8%), 117 (2.5%), 55 (4.0%), 41 (5.4%). 
HRMS (El) calculated for C3sH55BF2N202Si: 648.40940, found 648.41062. 
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4.2.28a Synthesis of (R)-7 -( 6-( 6-(tert-butyldimethylsilyloxy )-2,5, 7 ,8-
tetramethylchroman-2-yl)hexyl)-5,S-difluoro-l,3-dimethyl-SH -dipyrrolo[1,2-c: 1 ',2'-
f][1,3,2]diazaborinin-4-ium-S-uide (69a, n = 3)110 
A mixture of 68a (93.6 mg, 0.151 mmol) and Wilkinson's catalyst {69.8 mg, 
0.075 mmol) in absolute ethanol (25 ml) was shaken under an atmosphere of hydrogen 
gas (80 psi) for 52 h. Afterward, the crude product wa~ condensed in vacuo and purified 
via column chromatography (hexanes/diethyl ether 6: 1) to afford pure 69a (32.6 mg, 
0.052 mmol, 35%). 
Dark red oil, Rf = (0.50, hexanes/diethyl ether 3:2). IH NMR (300 MHz, CDCh) 
07.06 (s, IH), 6.91-6.89 (d, J = 3.9 Hz, IH), 6.28-6.27 (d, J = 3.9 Hz, IH), 6.08 (s, IH), 
3.00-2.94 (t, J = 7.8 Hz, 2H, BDP-C!!z), 2.56-2.53 (m, 5H, C4-Cfu, BDP-CH3), 2.24 (s, 
3H, Ar-C!:b), 2.10 (s, 3H, BDP-CH3), 2.08 (s, 3H, Ar-C!:b), 2.06 (s, 3H, Ar-C!:b), 1.87-
1.27 (m, 12H), 1.22 (s, 3H, C!:b), 1.05 (s, 9H, C(CH3)3), 0.14 (s, 6H, Si(C!:bh). 13C 
NMR (75 MHz, CDCh) 0 160.9, 158.9, 145.9, 144.0, 142.8, 134.6, 133.3, 128.5, 125.8, 
123.5, 123.1, 122.7, 119.8, 117.5, 116.7, 74.4, 39.6, 31.5, 29.9, 29.7, 28.7, 28.6, 26.1, 
23.8, 23.5, 20.9, 18.6, 14.8, 14.3, 13.4, 11.9, 11.2, -3.4. lIB NMR (96 MHz, CDCl) 1.29-
0.60 (t, J = 32.7 Hz, BF2)' 19F NMR (282 MHz, CDCh) -145.1 - -145.5 (overlapping q 
and sextet, J = 33.3 Hz, B5). MS (+EI) mlz 622 (M+, 2.6%), 433 (100%), 302 (2.8%), 
233 (16.5%), 208 (7.7%), 168 (53.1%), 149 (26.8%), 69 (12.2%), 55 (18.4%), 43 
(30.8%). HRMS (EI) calculated for C36H53BF2N202Si: 622.39375, found 622.39439. 
% 
4.2.2Sb Synthesis of (R)-7 -(7 -( 6-(tert-butyldimethylsilyloxy)-2,5, 7 ,S-
tetramethylchroman-2-yl)heptyl)-5,5-difluoro-l ,3-dimethyI -5H -dipyrrolo[1,2-c: l' ,2'-
f1[1,3,2]diazaborinin-4-ium-5-uide (69b, n = 4) 
(27.3 mg, 0.043 mmol, 58%). Dark red oil, Rf= (0.55, hexanes/diethyl ether 3:2). 
IH NMR (300 MHz, CDCh) ~ 7.06 (s, IH), 6.90-6.89 (d, J = 3.9 Hz, IH), 6.29-6.27 (d, J 
= 3.9 Hz, IH), 6.08 (s, IH), 2.99-2.94 (t, J = 7.8 Hz, 2H, BDP-Cfu), 2.56-2.53 (m, 5H, 
C4-Cfu, BDP-CH3), 2.24 (s, 3H, Ar-C!h), 2.10 (s, 3H, BDP-C!h), 2.08 (s, 3H, Ar-C!h), 
2.06 (s, 3H, Ar-C!h), 1.83-1.68 (m, 4H), 1.46-1.42 (m, 4H), 1.41-1.27 (m, 6H), 1.22 (s, 
3H, C!h), 1.05 (s, 9H, C(CH3h), 0.14 (s, 6H, Si(C!hh). J3C NMR (151 MHz, CDCh) ~ 
161.0, 158.9, 145.9, 144.0, 142.8, 134lj, 133.3, 128.5, 125.6, 123.5, 123.4, 122.7, 119.9, 
117.5, 116.9, 74.5, 39.6, 31.5, 30.0, 29.7, 29.5, 28.7, 28.6, 26.1, 23.8, 23.5, 20.9, 18.6, 
14.7, 14.2, 13.4, 12.0, 11.3, -3.3. liB NMR (96 MHz, CDCh) 1.29-0.60 (t, J = 32.7 Hz, 
BF2). 19p NMR (282 MHz, CDCh) -145.1 - -145.6 (overlapping q and sextet, J = 33.3 
Hz, B5). MS (+EI) mlz 636 (M+, 1.1%), 394 (46.0%), 380 (31.0%), 318 (5.4%), 248 
(13.0%),233 (100%), 213 (38.3%), 149 (6.1 %), 115 (2.4%),91 (14.8%),57 (4.5%),43 
(14.5%). HRMS (EI) calculated for C37H55BF2N202Si: 636.40940, found 636.40915. 
4.2.2Sc Synthesis of (R)-7-(S-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-
tetramethylchroman-2-yl)octyl)-5,5-difluoro-l,3-dimethyI-5H-dipyrrolo[1,2-c:l',2'-
f1[1,3,2]diazaborinin-4-ium-5-uide (69c, n = 5) 
(122.8 mg, 0.189 mmol, 70%). Dark red oil, Rf = (0.55, hexanes/diethyl ether 
3:2). IH NMR (300 MHz, CDCh) ~ 7.06 (s, IH), 6.91-6.89 (d, J = 3.9 Hz, IH),6.30-6.29 
(d, J = 3.9 Hz, IH), 6.08 (s, IH), 3.02-2.97 (t, J = 7.8 Hz, 2H, BDP-Cfu), 2.58-2.55 (m, 
SH, C4-Cfu, BDP-C!h), 2.24 (s, 3H, Ar-CH3), 2.13 (s, 3H, BDP-CH3), 2.11 (s, 3H, Ar-
97 
Cfu), 2.08 (s, 3H, Ar-Cfu) , 1.89-1.30 (m, 16H), 1.22 (s, 3H, Cfu), 1.05 (s, 9H, 
C(C!b)3), 0.14 (s, 6H, Si(C!b)2). I3C NMR (75 MHz, CDCb) ~ 160.9, 158.8, 145.9, 
144.0,142.7,134.5,133.3, 128.5,125.7,123.5,123.4,122.6, 119.8,117.4,116.8,74.4, 
39.6,31.5,29.6,29.5,29.4,29.3,28.7,28.6,26.1, 23.7, 23.6,20.9, 18.6, 14.8, 14.3, 13.4, 
11.9, 11.2, -3.4. l iB NMR (96 MHz, CDCh) 1.32-0.63 (t, J = 32.7 Hz, BF2). 19F NMR 
(282 MHz, CDCh) -145.0 - -145.4 (overlapping q and sextet, J = 33.0 Hz, BEz). MS 
(+EI) mlz 650 (M+, 4.1 %), 360 (14.2%), 346 (42.9%), 332 (26.2%), 233 (100%), 213 
(21.7%), 195 (6.3%), 149 (3.5%), 55 (2.1 %), 43 (4.2%). HRMS (EI) calculated for 
C3sH57BF2N202Si: 650.42505, found 650.42546. 
4.2.29a Synthesis of (R)-S,S-difluoro-7 -(6-( 6-hydroxy-2,S, 7 ,8-tetramethylchroman-2-
yI)hexyI)-l,3-dimethyl-SH -dipyrro)o[1,2-c: 1 ',2' -f][1,3,2]diazaborinin-4-ium-S-uide 
(42a, n = 3)117 
69a (30.0 mg, 0.048 mmol) was dissolved in tetrahydrofuran (1.2 ml) and a 10% 
solution of hydrochloric acid in methanol (1.2 ml) was added dropwise. The reaction 
stirred for 4.5 h and then was extracted in dichloromethane. Mter condensation, the 
crude residue was loaded onto a column (hexanes/diethyl ether 3:1) to afford final 
compound 42a (18.8 mg, 0.039 mmol, 77%). 
Dark red oil, Rf = (0.25, hexanes/diethyl ether 3:2), Rt = (25.8 min, acetonitrile, 
1.00 mllmin, pHPLC). Amax excitation in ethanol = 507 nm (£507 = 81 000 M-1cm-I ), Amax 
emission in ethanol = 511 nm. IH NMR (600 MHz, CDCI3) 07.08 (s, IH), 6.93-6.92 (d, 
98 
J = 3.9 Hz, 1H), 6.30-6.29 (d, J = 3.9 Hz, 1H), 6.11 (s, IH), 2.99-2.96 (t, J = 7.8 Hz, 2H, 
BDP-C!!z), 2.63-2.61 (t, J = 7.2 Hz, 2H, C4-C!!z), 2.58 (s, 3H, BDP-C!h), 2.27 (s, 3H, 
Ar-Cfu), 2.18 (s, 3H, BDP-C!h), 2.13 (s, 6H, 2xAr-Cfu), 1.84-1.71 (m,4H), 1.63-1.50 
(m, 2H), 1.47-1.41 (m,4H), 1.39-1.35 (m, 2H), 1.22 (s, 3H, C!h). 13C NMR (151 MHz, 
CDCh) 6 160.9, 159.0, 145.5, 144.5, 142.8, 134.6, 133.3, 128.5, 123.5, 122.6, 121.0, 
119.9,118.5,117.4,116.8,74.5,39.4,31.5,29.9,29.6,28.7, 28.6, 23.8, 23.5, 20.8,14.9, 
12.2, 11.8, 11.3. lIB NMR (96 MHz, CDCh) 1.28-0.60 (t, J = 32.7 Hz, BF2). 19F NMR 
(282 MHz, CDCh) -145.1 - -145.5 {overlapping q and sextet, J = 33.3 Hz, B5). MS 
(+El) mlz 508 (M+, 2.4%), 4g8 ([M-HFt, 44.4%),368 (2.8%), 325 (16.8%),277 (3.9%), 
227 (6.9%), 213 (14.2%), 149 (10.4%), 129 (19.1%), 112 (W.7%), 83 (15.2%), 71 
(16.2%), 57 (30.4%), 43 (100%). HRMS (El) calculated for C30H3SBFN202: 488.30104, 
found 488.30050. 
4.2.29b Synthesis of (R)-S,S-difluoro-7 -(7 -( 6-hydroxy-2,S,7 ,8-tetramethylchroman-2-
yl)heptyl)-1,3-dimethyl-SH-dipyrrolo[1,2-c: 1 ',2' -t][1,3,2]diazaborinin-4-ium-S-uide 
(42b, n = 4) 
(14.8 mg, 0.029 mmol, 66%). Dark red oil, Rf = (0.10, hexanes/diethyl ether 3:1), 
R, = (29.1 min, acetonitrile, 1.00 mllmin, pHPLC). Amax excitation in ethanol = 507 nm 
(£507 = 85 000 M-Icm-\ Amax emission in ethanol = 511 nm. IH NMR (600 MHz, 
CDCI3) 6 7.08 (s, IH), 6.93-6.92 (d, J = 3.9 Hz, IH), 6.30-6.29 {d, J = 3.9 Hz, IH), 6.11 
(s, IH), 2.99-2.98 (t, J = 7.8 Hz, 2H, BDP-C!h), 2.63-2.61 (t, J = 7.2 Hz, 2H, C4-Clh), 
2.58 (s, 3H, BDP-Cfu), 2.26 (s, 3H, Ar-CH3), 2.18 (s, 3H, BDP-C!h), 2.13 (s, 6H, 2xAr-
Cfu), 1.82-1.72 (m, 4H), 1.62-1.53 {m, 2H), 1.45-1.28 (m, 8H), 1.22 (s, 3H, Cfu). l3c 
NMR (151 MHz, CDCh) 6 161.0, 159.0, 145.5, 144.5, 142.8, 134.6, 133.3, 128.5, 123.5, 
99 
122.6, 121.0, 119.9, 118.5, 117.4, 116.8, 74.5, 39.5, 31.5, 30.0, 29.5, 29.4, 28.7, 28.6, 
23.8, 23.6, 20.8, 14.9,12.2, 11.8, 11.3. uB NMR (96 MHz, CDCh) 1.29-0.60 (t, J = 32.7 
Hz, BF2). 19F NMR (282 MHz, CDCh) -145.1 - -145.5 (overlapping q and sextet, J = 
33.0 Hz, B5). MS (+EI) mlz 522 (M+, 12.1 %),502 ([M-HFt, 100%), 368 {4.8%), 302 
(26.1 %), 227 (14.1%), 213 (25.1%), 205 (12.5%), 165 (12.8%), 149 (22.8%), 129 
(32.7%), 112 (19.5%), 86 (31.3%), 73 (49.7%), 57 (53.5%), 45 (26.1 %). HRMS (EI) 
calculated for C31HwBFN202: 502.31669, found 502.31872. 
4.2.29c Synthesis of (R)-5,5-difluoro-7 -(8-( 6-hydroxy-2,5, 7 ,8-tetramethylchroman-2-
yl)octyl)-1,3-dimethyl-5H -dipyrrolo[1,2-c: l' ,2' -f1[1,3,2]diazaborinin-4-ium-5-uide 
(42c, n = 5) 
(17.0 mg, 0.033 mmol, 74%). Dark red oil, Rf= (0.25, hexanes/diethyl ether 3:2), 
Rt = (33.4 min, acetonitrile, 1.00 mllmin, pHPLC). Amax excitation in ethanol = 507 nm 
(£507 = 83 000 M-1cm-I), "'max emission in ethanol = 511 nm. IH NMR (600 MHz, 
CDCh) 07.08 (s, 1H), 6.93-6.92 (d, J = 3.9 Hz, 1H), 6.31-6.30 (d, J = 3.9 Hz, IH), 6.11 
(s, 1H), 2.99-2.97 (t, J = 7.8 Hz, 2H, BDP-Cfu), 2.63-2.61 (t, J = 7.2 Hz, 2H, C4-Cfu), 
2.58 (s, 3H, BDP-Cfu), 2.26 (s, 3H, Ar-CH3), 2.18 (s, 3H, BDP-Cfu), 2.13 (s, 6H, 2xAr-
Cfu), 1.84-1.71 (m,4H), 1.62-1.54 (m, 2H), 1.44-1.41 (m,4H), 1.35-1.28 (m, 6H), 1.23 
(s, 3H, Cfu). l3C NMR (151 MHz, CDCh) 0 161.0, 159.0, 145.5, 144.5, 142.8, 134.6, 
133.3,128.5,123.5, 122.6, 121.0, 119.9,118.5,117.4,116.9, 74.5, 39.5, 31.5, 30.1,29.6, 
29.5,29.4,28.7,28.6,23.8,23.6,20.8,14.9, 12.2, 11.8, 11.3. lIB NMR (96 MHz, CDCh) 
1.29-0.60 (t, J = 32.7 Hz, BF2)' 19F NMR (282 MHz, CDCh) -145.2 - -145.5 
(overlapping q and sextet, J = 33.0 Hz, BF?). MS (+EI) m/z 536 (M+, 1.4%), 516 ([M-
HFt, 36.8%),408 (3.1%), 353 (10.1%), 298 (33.3%), 278 (3.6%), 233 (17:6%),213 
100 
(18.4%),191 (3.8%), 171 (100%), 129 (14.1%), 97 (17.0%), 69 (22.3%), 55 (33.3%),43 
(47.1%). HRMS (EI) calculated for C32H42BFN202: 516.33234, found 516.33308. 
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4.2.30 Synthesis of tert-butyI2-bromo-lH-pyrrole-l-carboxylate (83)134 
Pyrrole (5.00 g, 74.5 mmol) wali dissolved in tetrahydrofuran (200 ml) and 'Cooled 
to - 78°C under nitrogen. l,l-Azobis(cyclohexanecarbonitrile) (182 mg, 0.745 mmol) 
was then added and the mixture stirred for 5 min. Over the course of 15 min, 1,3-
dibromo-5,5'-dimethylhydantoin (10.7 g, 37.3 mmol) was slowly added and the solution 
stirred for an additional 10 min. Next, the reaction mixture stood for 2 h while 
maintaining a temperature below -50°C. This mixture was then filtered via suction and 
TEA (4.15 ml, 29.8 mmol), BOC20 (24.0 ml, 0.104 mol), and DMAP (91.0 mg, 0.745 
mmol) were added to the stirring filtratea ali it was warmed to room temperature. After 
stirring overnight, the crude material wali condensed in vacuo and extracted with 
dichloromethane. Purification by silica gel chromatography (hexanes/ethyl acetate 20:1) 
afforded pure 83 (16.4 g, 67.0 mmol, 90%). 
Clear and colourless oil, Rf = (0.50, hexanes/ethyl acetate 10: 1). IH NMR (300 
MHz, CDCh) () 7.30-7.25 (dd, J = 3.6 Hz, J' = 1.8 Hz, lH, CHN), 6.23-6.22 (dd, J = 3.6 
Hz, J' = 1.8 Hz, IH, CHCBr), 6.09-6.07 (dd, J = 3.6 Hz, IH), 1.56 (s, 9H, qCfuh). 13C 
NMR (75 MHz, CDCl) () 147.5, 122.6, 116.8, 111.2,99.8,84.2,27.5. MS (+EI) miz 245 
(M+, 12.1 %), 186 (4.1 %), 172 (11.3%), 145 (48.6%), 119 {2.1 %),64 (5.5%),57 (100%), 
41 (45.4%). HRMS (EI) calculated for C9H12N02Br: 245.00514, found 245.00512. 
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4.2.31 Synthesis of tert-butyI2-(thiophen-2-yl)-lH-pyrrole-1-carboxylate (88)83 
To a solution of 83 (1.30 g, 5.28 mmol) and 2-thienylboronic acid (450 mg, 3.52 
mmol) in n-butanol wa"l added palladium (II) acetate 05.8 mg, 0.070 mmol), SPhos (57.7 
mg, 0.141 mmol), and potassium phosphate tribasic (1.49 g, 7.03 mmol). The reaction 
was then heated to 100°C for 5 h. Mterward, the solution was wa"lhed with water and 
the organic layer was collected, condensed · in vacuo, and the crude material was purifed 
by silica gel chromatography (hexanes/ethyl acetate 30:1) to yield 88 (656 mg, 2.63 
mmol,75%). 
Light yellow oil, Rf = (0.30, hexanes/ethyl acetate 20:1). IH NMR (300 MHz, 
CDCh) 87.42-7.40 (dd, J = 3.3 Hz, J' = 1.8 Hz, IH), 7.33-7.31 (dd, J = 5.1 Hz, J' = 0.9 
Hz, 1H), 7.10-7.08 (dd, J = 3.6 Hz, J' = J = 0.9 Hz, IH), 7.05-7.02 (dd. J = 5.1 Hz, J' = 
3.6 Hz, 1H), 6.35-6.34 (dd, J = 3.3 Hz, J' = 1.8, IH), 6.25-6.23 (dd, J = 3.3 Hz, J' = 3.3 
Hz, IH), 1.46 (s, 9H, C(C!b)3). l3C NMR (75 MHz, CDCh) 8148.9, 134.8, 127.6, 126.7, 
126.3, 125.4, 123.0, 116.5, 110.4, 83.6, 27.5. MS (+EI) mil. 249 (M+, 13.2%), 193 
(48.7%), 176 (5.3%), 149 (90.8%), 104 00.2%), 57 (100%), 41 (27.4%). HRMS (EI) 
calculated for Cl3H1sN02S: 249.08235, found 249.08236. 
4.2.32 Synthesis of 5-(thiophen-2-yl)-lH-pyrrole-2-carbaldehyde (89)144 
To a solution of N,N-dimethylformamide (40.8 Ill, 0.529 mmol) in 1,2-
dichloroethane 0 ml) at 0 °C was slowly added phosphorus oxychloride (48.5 Ill, n.S29 
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mmol). The reaction mixture was then warmed to room temperature for 2 h. It was 
cooled to 0 °C again to allow the slow addition of 88 (120 mg, 0.481 mmol) in 1,2-
dichloroethane (2.4 mI). The reflux went for I h. Then a solution of sodium acetate (360 
mg) in water (1 ml) was added and boiling continued for 1 h. The organic layer was 
collected and condensed in vacuo. Flash chromatography (hexanes/ethyl acetate 8: 1) was 
performed to obtain pure 89 (50.0 mg, 0.282 mmol, 59%). 
Light yellow oil, Rf = (0.10, hexanes/ethyl acetate 10: 1). lH NMR (300 MHz, 
CDCI3) a 10.01 (br s, IH, NH), 9.50 (s, IH, CHO), 7.41-7.40 (d, J = 3.3 Hz, IH), 7.33-
7.31 (d, J = 5.1 Hz, IH), 7.10-7.08 (dd, J = 4.2 Hz, J' = 4.2 Hz, 1H), 7.01-6.99 (dd, J = 
2.9 Hz. J' = 2.9 Hz, IH), 6.54-6.52 (dd, J = 2.9 Hz, J' = 2.9 Hz, IH). 13C NMR (75 MHz, 
CDC h) a 178.6,134.8,133.7,132.9,128.2,125.8,124.4,122.9,109.4. MS (+EI) m/z 177 
(M+, 100%), 148 (7.7%), 121 (30.0%), 104 (4.7%), 74 (5.6%), 63 (5.2%), 51 (4.6%),45 
(8.4%). HRMS (EI) calculated for C9H7NOS: 177.02484, found 177.02482. 
4.2.33 Synthesis of 5,5-difluoro-7 -(pent-4-enyl)-3-( thiophen-2-yl)-SH -dipyrrolo[1,2-
c:l' ,2'-f][1,3,2]diazaborinin-4-ium-5-uide (94)46 
Crude 92 and 89 (190 mg, 1.70 mmol) were dissolved in dry dichloromethane (16 
ml) and cooled to 0 °C under nitrogen. A solution of phosphorus oxychloride (98.1 J.ll, 
1.70 mmol) in dichloromethane (l ml) wa~ added via syringe and this was kept on ice for 
5 h. Afterward, boron trifluoride diethyl etherate (544, . .tl, 4.30 mmol) and DIPEA (748 
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ml, 4.30 mmol) were added and stirring was continued for overnight at room temperature. 
The crude product wa~ extracted in dichloromethane and condensed in vacuo. The 
residue wa~ purified by silica gel chromatography (hexanes/diethyl ether 3: 1) to afford 
pure 94 (83.2 mg, 0.243 mmol, II % over two steps). 
Dark purple oil, Rf = (0.40, hexanes/diethyl ether 3:2). Amax excitation in ethanol 
= 561 nm (£561 = 78 000 M-1cm-I), Amax emission in ethanol = 570 nm. IH NMR (300 
MHz, CDCh) 0 8.16-8.15 (d, J = 3.6 Hz, IH), 7.47-7.45 (d, J = 5.1 Hz, IH), 7.19-7.16 
(dd, J = 4.8 Hz, J = 4.2 Hz, IH), 7.05 (s, IH), 6.96-6.93 (dd, J = J = 4.5 Hz, 2H), 6.74-
6.73 (d, J = 4.2 Hz, IH), 6.38-6.37 (d, J = 4.2 Hz, IH), 5.95-5.81 (ddt, J = 17.0 Hz, J' = 
10.3 Hz, J" = 6.7 Hz, IH, CH=CH2), 5.12-5.01 (m, 2H, CH=CH2), 3.11-3.05 (t, J = 7.8 
Hz, 2H, TBDP-C!h), 2.26-2.19 (m, 2H, C!hCH=CH2), 1.92-1.82 (m, 2H). l3C NMR (75 
MHz, CDCI3) S 163.6, 149.7, 138.0, 136.2, 134.8, 134.1, 130.7, 130.6, 130.1, 129.7, 
128.8, 126.2, 119.6, 118.9, 115.1,33.5,28.4,27.8. liB NMR (96 MHz, CDCh) 1.72-1.03 
(t, J = 24.1 Hz, BF2). 19p NMR (282 MHz, CDCh) -141.8 - -142.1 (overlapping q and 
sextet, J = 33.3 Hz, BEz). MS (+EI) mlz 342 (M+, 60.7%), 328 (4.3%), 300 (22.1 %),287 
(100%), 260 (16.6%), 231 (8.8%),218 (19.0%), 205 (49.4%), 186 (6.4%), 162 (5.7%), 
149 (15.7%), 121 (5.7%), 93 (4.2%), 80 (5.7%), 57 (6.1 %), 41 (4.2%). HRMS (EI) 
calculated for C1sHI7BF2N2S: 342.11736, found 342.11730. 
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4.2.34 Synthesis of (8,E)-7 -{5-( 6-(tert-butyldimethylsilyloxy)-2,S,7 ,8-
tetramethylchroman-2-yl)pent-4-enyl)-S,5-difluoro-3-(thiophen-2-yl)-5H-dipyrrolo 
[l,2-c: l' ,2' -f][l,3,2]diazaborinin-4-ium-5-uide (95)43 
Vinyl Ttolox 61 (104 mg, 0.299 mmol) and pentenylTBDP 94 (205 mg, 0.,98 
mmol) were dissolved in dry dichloromethane (2.4 mI). Catalyst C-S71 from Materia, 
Inc. (o-tolyl derivative of Hoveyda-Grubbs Catalyst 2nd Generation, 81) (17.0 mg, 0.030 
mmol) was then added and the reaction refluxed for 9 h. The mixture was condensed in 
vacuo and the crude residue was purifted by silica gel chromatography (hexanesldiethyl 
ether 6:1) to obtain 9S (27.8 mg, 0.042 mmol, 14%). 
Dark purple oil, Rf = (0.35, hexanes/dietbyl ether 3:2). IH NMR (300 MHz, 
CDCh) 8 8.15-8.14 (d, J = 3.6 Hz, IH), 7.48-7.47 {m, IH), 7.21-7.15 (m, 1H), 7.09 (s, 
1H), 7.02-6.99 (m, 2H), 6.78-6.77 (d, J = 3.6 Hz, 1H), 6.32-6.31 (d, J = 4.2 Hz, 1H), 
5.58-5.55 (m, 2H, CH=CH), 3.01-2.93 em, 2H, TBDP-C!!z), 2.56-2.50 (m, 2H, C4-C!!z), 
2.15 (s, 3H, Ar-ClL), 2.13 (s, 3H, Ar-ClL), 2.04 (s, 3H, Ar-ClL), 1.97-1.74 (m, 6H), 
1.40 (s, 3H, ClL), 1.06 (s, 9H, C{ClLh), 0.13 (s, 6H, Si(ClLh). l3c NMR (151 MHz, 
CDCh) 8 164.1, 149.7, 146.1, 144.2, 136.3, 134.7, 134.5, 134.2, 131.6, 130.7, 130.6, 
130.2, 129.6, 128.8, 126.2, 125.8, 123.5, 122.3, 119.3, 118.8, 117.7, 77.2, 32.4, 31.6, 
29.4,28.4,27.3,26.1,21.2, 18.6, 14.4, 13.4, 12.1, -3.3. llB NMR (96 MHz, CDCh) 1.68-
1.00 (t, J = 32.7 Hz, BF2). 19F NMR (282 MHz, CDCh) -141.9 - -142.4 (overlapping q 
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and sextet, J = 32.5 Hz, B5). MS (+EI) mlz 660 (M+, 7.3%),640 (6.5%), 578 (6.4%), 
450 (4.8%), 368 (9.1 %), 342 (80.9%), 319 (100%), 294 (72.9%), 262 (28.2%), 221 
(20.6%), 183 (42.5%), 149 (20.8%), 117 (13.6%), 73 (68.5%), 55 (37.5%),43 (37.5%). 
HRMS (EI) calculated for C37RnBF2N20 2SSi: 660.31887, found 660.31961. 
4.3 Fluorescent Binding Assay Protocol 
4.3.1 Preparation of Ligand Stocks 
Synthetic fluorescent analogues and natural ligands were assessed for purity by 
NMR and HPLC prior to preparation of concentrated stocks (0.030-0.200 rnM) in 
absolute ethanol. These stock solutions were stored at 4 °C until required and protected 
from direct exposure to light. Working, diluted stocks were freshly prepared in absolute 
ethanol at desired concentrations, mixed thoroughly by vortexing and kept on ice while 
performing the binding assays. 
4.3.2 Fluorescence Measurements 
Steady state fluorescence was measured using a spectrofluorometer employing 
right angle illumination with a 150 W xenon lamp. All measurements were made at 115 
W with excitation and emission slit widths of 5 nm and at an excitation of 506 nm. 
Equilibrium fluorescence binding data was analyzed using non-linear least-squares 
regression analysis fitted to a one-site binding equation 145 using Graphpad Prism 4.0 
software. 
4.3.3 Fluorescence Titration Assay 
All titration assays for BDP-a-Tocs 42a-c were performed similarly unless 
otherwise noted. 
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Titrations were perfom1ed in a glass cuvette containing a total reaction volume of 
3 ml SET buffer and protein sample. Sufficient stock of u-TIP (typically less than 50 'Ill) 
was added such that the final protein concentration was 1.0 J..LM. The sample was then 
well-mixed by repeated inversion and a baseline fluorescence measurement was l"ecorded 
at 506 nm. To this solution were added aliquots (0.6-2.0 Ill) of working fluorophore 
stock solutions (0.030-0.200 mM). Generally after 20 min of end-over-end mixing using 
a Roto-Torque® rotating mixer, the signal had reached a maximum and the emission 
spectrum was recorded. Working stock solutions were prepared such that the final 
concentration of ethanol did not exceed 2% v/v. No-protein controls involved titration of 
fluorescent tocopherols into SET buffer under identical conditions and at identical 
concentrations. 
4.3.4 Fluorescence Competition Assay 
Competition assays were performed under similar conditions as section 4.3.3. To 
a 0.2 JlM solution of u-TIP in 3 ml SET buffer was added 2 III of a stock solution of 
fluorescent analogue in absolute ethanol (1.5 mM) such that the final concentration of 
analogue was 1 JlM. The solution was then mixed until the fluorescence signal remained 
the same (equilibrium was reached). To this solution were added 2 III aliquots of u-
tocopherol in absolute ethanol (1.5 mM to 15 mM) to yield final concentrations of 
tocopherol ranging from 1 to 40 JlM. After each addition of tocopherol, the samples were 
mixed for 15 min to attain equilibrium, and the final fluorescence recorded. Contml 
experiments included an identical competition substituting cholesterol as the competitor. 
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